Endocrinology and Metabolism

Original Articles

Steatotic Liver Disease Subtypes and Advanced Fibrosis as Independent Predictors of Ischemic Stroke in Type 2 Diabetes Mellitus: Myunghwa Jang, Gyuri Kim, Kyu-na Lee, Rosa Oh, So Hyun Cho, Ji Yoon Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim; Received November 15, 2025 Accepted February 13, 2026 Published online May 18, 2026; DOI: https://doi.org/10.3803/EnM.2025.2792 [Epub ahead of print]

518 View
15 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Although type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) are associated with an increased risk of ischemic stroke, the extent to which steatotic liver disease (SLD) subtypes and advanced liver fibrosis confer additional risk in individuals with T2DM remains unclear. We aimed to investigate the association of SLD categories and/or advanced liver fibrosis with ischemic stroke risk among patients with T2DM.
Methods
A total of 2,220,249 patients with T2DM were classified into five groups: no steatosis, MASLD, MASLD with other combined disease, metabolic dysfunction and alcohol-related steatotic liver disease (MetALD), and alcohol-related liver disease (ALD) with metabolic dysfunction (MD). SLD was defined using a fatty liver index (FLI) of ≥30, and advanced fibrosis was defined by a BARD score of ≥2.
Results
Over a median follow-up of 11 years, 135,482 ischemic strokes (6.10%) occurred. Compared with no steatosis, adjusted hazard ratios (aHRs) for stroke were higher in MASLD (aHR, 1.10; 95% confidence interval [CI], 1.08 to 1.11), MASLD with combined disease (aHR, 1.14; 95% CI, 1.12 to 1.17), MetALD (aHR, 1.13; 95% CI, 1.11 to 1.16), and ALD with MD (aHR, 1.32; 95% CI, 1.27 to 1.37). Advanced fibrosis progressively increased stroke risk compared with non-SLD and non-fibrotic SLD. Compared with the FLI <30 group, those with FLI 30–60 and ≥60 showed increased aHRs for stroke. Very heavy drinking was associated with a further increase in risk compared with non-drinking.
Conclusion
In patients with T2DM, all SLD categories and advanced liver fibrosis were associated with an increased risk of ischemic stroke. Very heavy alcohol consumption was generally associated with a higher stroke risk across FLI categories.

YTHDF1-Mediated m⁶A Modification of lncRNA OIP5-AS1 Exacerbates Macrophage Metabolic Dysfunction in Diabetes Mellitus with Coronary Artery Disease: Hongjie Wang, Luyao Li, Zhen Zhen, Zheqi Zhang, Ya Su, Bo Li; Received July 21, 2025 Accepted December 15, 2025 Published online May 7, 2026; DOI: https://doi.org/10.3803/EnM.2025.2566 [Epub ahead of print]

523 View
15 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Diabetes mellitus (DM) with coronary artery disease (CAD), referred to as DM-CAD, is a prevalent endocrine-metabolic condition characterized by macrophage-driven inflammation and metabolic dysregulation. This study aims to investigate the role of YTH N6-methyladenosine RNA binding protein F1 (YTHDF1)-mediated N⁶-methyladenosine (m⁶A) modification in stabilizing the long non-coding RNA (lncRNA) Opa interacting protein 5 antisense RNA 1 (OIP5-AS1) and to determine its impact on macrophage metabolic dysfunction in DM-CAD.
Methods
Single-cell RNA sequencing and bulk RNA sequencing were performed using DM-CAD mouse models, with downstream analyses conducted using Seurat, CellChat, least absolute shrinkage and selection operator (LASSO) regression, and random forest algorithms. Experimental validation included RNA immunoprecipitation followed by quantitative polymerase chain reaction, actinomycin D-based RNA stability assays, and 2-deoxyglucose (2-DG) interventions in THP-1–derived macrophages, alongside metabolomic profiling and reactive oxygen species (ROS) measurements.
Results
Increased macrophage-endothelial cell coupling was observed in DM-CAD, with both OIP5-AS1 and YTHDF1 significantly upregulated and closely associated with glycolytic metabolic pathways. YTHDF1-mediated m⁶A modification stabilized OIP5-AS1, thereby promoting glycolysis, foam cell formation, ROS production, plaque development, and the upregulation of proinflammatory cytokines, collectively exacerbating atherosclerosis. Notably, treatment with 2-DG markedly reversed these pathological phenotypes.
Conclusion
This study identifies the YTHDF1–m⁶A–OIP5-AS1 axis as a critical regulator of macrophage metabolic dysfunction in DM-CAD, thereby providing an epigenetic framework for understanding disease progression. Targeting this regulatory pathway may attenuate metabolic inflammation and represents a promising therapeutic strategy for endocrine-related cardiovascular complications.

Association between Prolactinoma and Incident Type 2 Diabetes Mellitus: Evidence from a Korean Nationwide Cohort: Han Na Jung, Bo Ram Yang, Min-Seon Kim, Jeong-Hwa Yoon, Se Hee Min; Received June 17, 2025 Accepted November 5, 2025 Published online May 6, 2026; DOI: https://doi.org/10.3803/EnM.2025.2508 [Epub ahead of print]

441 View
14 Download

Abstract PDF Supplementary Material PubReader ePub: Background
The effect of prolactinoma on the development of type 2 diabetes mellitus (T2DM) has not been evaluated at the population level. We investigated the association between prolactinoma and incident T2DM in a nationwide cohort.
Methods
We analyzed data from the Korean National Health Insurance Service–National Sample Cohort, which includes 2% of the total national population selected by random sampling, covering the period from 2002 to 2019. A total of 335 patients with newly diagnosed prolactinoma and 1,562 age- and sex-matched controls were included. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for T2DM using Cox proportional hazards regression. Time-dependent HRs were also estimated.
Results
The proportion of prolactinoma patients who developed T2DM was significantly higher than that of controls (10.1% vs. 5.5%; relative risk, 1.84; 95% CI, 1.26 to 2.69). After adjustment for age, sex, income, and comorbidities, the risk of T2DM remained significantly higher in the prolactinoma group (HR, 1.56; 95% CI, 1.01 to 2.41). Subgroup analysis showed a markedly increased risk among individuals aged ≥50 years (HR, 4.47; 95% CI, 1.66 to 12.08). The positive association between prolactinoma and T2DM decreased over time but remained significant for up to 3 years after prolactinoma diagnosis (HR, 9.28 [95% CI, 3.45 to 24.97]; HR, 3.15 [95% CI, 1.55 to 6.38]; and HR, 0.82 [95% CI, 0.44 to 1.53] for ≤1, 1–3, and >3 years, respectively).
Conclusion
Newly diagnosed prolactinoma was independently associated with a higher risk of T2DM, with the association diminishing over 3 years. These findings highlight the importance of monitoring for T2DM during the early management of prolactinoma, particularly in middle-aged patients who may have been previously overlooked.

Sex Disparity in Suicide Mortality among Patients with Type 2 Diabetes: A Nationwide Population-Based Cohort Study: Chaiho Jeong, Bongseong Kim, Dae Jong Oh, Tae-Seo Sohn, Kyungdo Han, Hyuk-Sang Kwon; Received September 16, 2025 Accepted November 24, 2025 Published online March 19, 2026; DOI: https://doi.org/10.3803/EnM.2025.2669 [Epub ahead of print]

732 View
22 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Suicide represents a major public health concern in Korea. Patients with type 2 diabetes mellitus (T2DM) are at higher risk for psychological distress and suicide. Although the male-to-female suicide mortality ratio in the general population has remained about 2.3, the specific differences in suicide mortality by sex among individuals with T2DM are not well characterized.
Methods
We performed a nationwide cohort study utilizing the Korean National Health Insurance Service database, identifying 2,526,769 adults with T2DM who underwent health screening from 2015 to 2016. Participants were monitored until the occurrence of suicide or the study endpoint.
Results
During a median follow-up of 6.0 years, 5,584 suicide deaths occurred (0.30% in men vs. 0.10% in women). Men exhibited a significantly elevated risk of suicide mortality compared to women (adjusted hazard ratio [HR], 2.88; 95% confidence interval [CI], 2.66 to 3.12). The largest disparity was observed in the ≥80 age group (HR, 3.60; 95% CI, 2.88 to 4.51). However, this sex disparity in suicide mortality was reduced among current smokers and heavy alcohol consumers. Among non-smokers, the HR comparing men to women was 3.51 (95% CI, 3.22 to 3.83), while among current smokers, it was 1.73 (95% CI, 1.40 to 2.14). Similarly, the HR among non-drinkers was 3.04 (95% CI, 2.79 to 3.31), compared with 1.36 (95% CI, 0.85 to 2.18) among heavy drinkers.
Conclusion
Men with T2DM had a significantly higher risk of suicide mortality than women, exceeding the sex disparity seen in the general population, with the gap further influenced by age and lifestyle factors.

Review Article

Miscellaneous Big Data Articles (National Health Insurance Service Database)
Nationwide Big Data Studies of Endocrine Diseases Using the Korean National Health Information Database: Research Trends and Standardization of Operational Definitions: Sun Wook Cho, Jung Hee Kim, Kyoung Jin Kim, Beom-Jun Kim, Mee Kyoung Kim, Eun Jung Rhee; Endocrinol Metab. 2026;41(1):86-104. Published online February 26, 2026; DOI: https://doi.org/10.3803/EnM.2026.2953

1,617 View
51 Download
2 Web of Science
2 Crossref

Abstract PDF PubReader ePub

The Korean National Health Information Database (NHID) is a large-scale dataset created through linkage of National Health Insurance claims with nationwide health screening records. Because it is released in a cohort-based format, the NHID enables longitudinal follow-up and allows investigation of rare endocrine conditions with low population prevalence. Mortality data, including both dates and causes of death, are additionally obtained through linkage with Statistics Korea. Over recent years, use of the NHID has expanded rapidly, establishing it as a major resource for epidemiological research in endocrinology. Nevertheless, because the database was originally developed for administrative and screening purposes rather than for research, investigators face several methodological limitations, particularly the need to construct and validate robust operational definitions of diseases. In this review, we describe the key features of the Korean NHID, summarize operational definitions of endocrine disorders that have been applied in prior research, and provide an overview of recent endocrine studies conducted using this database.

Citations

Citations to this article as recorded by

Age-specific loss of life expectancy after hip fracture in Asian adults: A nationwide population-based cohort study
Kyoung Jin Kim, Su Jin Kwon, Seunghyun Lee, Seong Hee Ahn, So Young Park, Ha-Young Kim, Kyoung Min Kim
Bone.2026; 208: 117896. CrossRef
Diabetes progression and its association with fracture risk in type 2 diabetes
Bongsung Kim, Kyu-Na Lee, Kyungdo Han, Mee Kyoung Kim
Osteoporosis International.2026;[Epub] CrossRef

Songwon Lecture 2025

Diabetes, obesity and metabolism
Postpartum Glucose Intolerance in Women with a History of Gestational Diabetes Mellitus: An In-Depth Review: Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho; Endocrinol Metab. 2026;41(1):26-33. Published online February 3, 2026; DOI: https://doi.org/10.3803/EnM.2025.2852

1,809 View
68 Download
1 Web of Science
1 Crossref

Abstract PDF PubReader ePub

Gestational diabetes mellitus (GDM) is increasing in prevalence worldwide, and postpartum glucose intolerance represents one of the major complications after delivery in women with GDM. A wide range of risk factors for postpartum glucose intolerance have been identified, including ethnicity, genetic predisposition, age, obesity, pre-pregnancy body mass index, gestational weight gain, history of GDM, family history of diabetes, degree of hyperglycemia, insulin treatment, lipid profiles, and other metabolic factors. Lifestyle interventions, including weight loss, are thought to reduce the risk of postpartum glucose intolerance. Careful attention should be paid to the screening of postpartum glucose intolerance in women with GDM, and concerted efforts should be made to prevent or delay the development of diabetes and other metabolic disorders.

Citations

Citations to this article as recorded by

Diabetes in Pregnancy in Korea: Prevalence, Clinical Characteristics, and Postpartum Comorbidities
Joon Ho Moon, Han Na Jung, Bongseong Kim, Seung-Hyun Ko, Soo Heon Kwak, Kyung-Do Han, Sung Hee Choi
Diabetes & Metabolism Journal.2026; 50(2): 280. CrossRef

Original Articles

Decline in Years of Life Lost Due to Diabetes in Korea, 2008–2019: A Cause-Specific Decomposition Analysis: Da Hea Seo, Kyoung Hwa Ha, Dae Jung Kim; Received August 24, 2025 Accepted November 10, 2025 Published online January 28, 2026; DOI: https://doi.org/10.3803/EnM.2025.2622 [Epub ahead of print]

1,208 View
30 Download
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study aimed to evaluate trends in years of life lost (YLL) attributable to diabetes and to identify cause-specific contributors to these changes in Korea.
Methods
We analyzed data from the Korean National Health Insurance Service-National Sample Cohort between 2008 and 2019. Standardized mortality ratios (SMRs) were calculated using indirect standardization with age-specific mortality rates of individuals without diabetes as the reference. YLL was defined as the difference in life expectancy between individuals with and without diabetes at a given age. Cause-specific contributions to changes in YLL were estimated using Arriaga’s decomposition method.
Results
From 2008 to 2019, SMRs declined from 2.19 to 1.55 in males and from 2.04 to 1.36 in females. At age 40, life expectancy among individuals with diabetes increased from 32.53 to 37.81 years in males and from 39.41 to 43.77 years in females, accompanied by a reduction in diabetes-attributable YLL from 8.36 to 5.70 years in males and from 7.51 to 5.21 years in females, representing an approximate 30% decrease. The YLL gap narrowed with increasing age. At age 40, cause-specific decomposition showed that the largest relative reductions in YLL were attributable to diabetes (–40% in males, –46% in females), cardiovascular disease (–37% in males, –52% in females), and kidney disease (–33% in both sexes).
Conclusion
Diabetes-related YLL in Korea declined substantially over the past decade, primarily driven by reductions in mortality from diabetes, cardiovascular disease, and kidney disease.

Citations

Citations to this article as recorded by

Female Gender and Life Expectancy: Systematic Review with ☸️SAIMSARA

SAIMSARA Journal.2026;[Epub] CrossRef

Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol (SMART-5 Study): Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin; Received July 26, 2025 Accepted October 13, 2025 Published online December 12, 2025; DOI: https://doi.org/10.3803/EnM.2025.2579 [Epub ahead of print]

2,139 View
68 Download

Abstract PDF PubReader ePub: Background
Stage 2 or 3 connected insulin pens (CIPs) refer to tracking insulin pens that are capable of transmitting insulin dose data via cloud connectivity. Stage 4 CIPs feature a bolus calculator that determines appropriate insulin doses based on real-time continuous glucose monitoring (CGM) data, carbohydrate intake, previous dosing history, and preset parameters. Stage 5 CIPs additionally offer advanced decision-support features, such as education modules and coaching. However, the efficacy and safety of Stage 5 CIPs have not yet been established.
Methods
In this prospective, open-label, parallel-group, multicenter, randomized controlled trial, we will include adults aged ≥19 and <75 years with type 1 or type 2 diabetes receiving multiple daily insulin injections (MDI) and having glycosylated hemoglobin (HbA1c) levels of 7.5% to 12.0%. In total, 152 participants will be randomized in a 1:1 ratio to receive either Stage 5 CIPs with CGM or tracking insulin pens with CGM. Stage 5 CIPs include a Setup Wizard that recommends individualized initial settings and an algorithm that provides advanced insulin dosing guidance based on analyses of each participant’s CGM and insulin injection data. The primary outcome will be the change in HbA1c levels from baseline to week 12 (ClinicalTrials.gov, NCT07004153).
Conclusion
This trial (Stage 5 connected insulin pen for MDI with Advanced decision support in a Randomized Trial [SMART-5 Study]) will determine whether Stage 5 CIPs are superior to tracking insulin pens in improving glycemic control among adults with type 1 or type 2 diabetes treated with MDI. Overall, this study may offer a promising strategy for enhancing the management and outcomes of patients with diabetes.

Diabetes, obesity and metabolism
Impact of Carbohydrate Intake Fluctuations on Glucose Profiles: Insights from Continuous Glucose Monitoring-Based Patient Clustering: Hyun Ah Kim, Kyung Hee Kim, Young Lee, Yoon-Ju Song, Joon Ho Moon, Sung Hee Choi, Tae Jung Oh; Endocrinol Metab. 2026;41(1):152-161. Published online December 12, 2025; DOI: https://doi.org/10.3803/EnM.2025.2486

1,953 View
88 Download

Abstract PDF PubReader ePub: Background
Continuous glucose monitoring (CGM) is widely applied in daily glucose management. However, its potential to categorize individuals based on glucose profiles is not fully established. This study employed CGM-based patient clustering and examined nutritional factors influencing glucose patterns.
Methods
This prospective observational study enrolled 34 individuals with diabetes. Retrospective professional CGM was conducted over 7 days, during which food intake was recorded. K-means clustering was performed using CGM-derived coefficient of variation (CV) and time in range. Macronutrient intake and its fluctuations were compared across clusters.
Results
Participants were grouped into cluster 1 (well-controlled), cluster 2 (highest CV), and cluster 3 (highest mean glucose). Baseline clinical characteristics, daily energy intake (kcal), and macronutrient intake did not differ significantly among clusters. However, carbohydrate intake fluctuations were greater in cluster 3 (CV 41.0%±32.1%, standard deviation [SD] 502.1±363.4 kcal) than in cluster 1 (CV 21.9%±9.0%, SD 260.2±94.1 kcal) and cluster 2 (CV 19.2%±9.1%, SD 250.2±126.1 kcal) (P=0.123 for CV; P=0.024 for SD). The SD (kcal) of carbohydrate intake was positively correlated with mean glucose levels (rho=0.88, P=0.023).
Conclusion
CGM enables categorization of individuals based on glucose profiles, and higher carbohydrate intake fluctuations are associated with poorer glycemic control. Personalized dietary strategies, particularly stabilizing carbohydrate intake, may support better glucose management in individuals with high mean glucose and low CV.

Diabetes, obesity and metabolism
Distinct Pituitary-Adrenal Responses to Hypoglycemia in Type 1 and Type 2 Diabetes: Yun Hu, Reng-na Yan, Ting-ting Cai, Xiao-wei Zhu, Jian-hua Ma, Bo Ding; Endocrinol Metab. 2026;41(1):162-173. Published online December 3, 2025; DOI: https://doi.org/10.3803/EnM.2025.2479

1,643 View
67 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Hypoglycemia remains a major barrier to optimal glycemic control in diabetes. Counter-regulatory hormonal responses, particularly those involving the pituitary and adrenal systems, play a central role in mitigating hypoglycemia, yet differences between diabetes subtypes are not well characterized. We aimed to investigate pituitary-target gland responses to hypoglycemia in patients with type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM).
Methods
We enrolled drug-naive patients with newly diagnosed T2DM or T1DM, along with controls who did not have diabetes. Participants with diabetes received insulin pump therapy until normoglycemia was achieved. Hyperinsulinemic euglycemic-hypoglycemic clamps were then performed in all participants. Hormonal profiles of the pituitary-adrenal axis and C-peptide were serially measured during the clamps.
Results
During hypoglycemic clamps, C-peptide, thyroid-stimulating hormone, estradiol, and testosterone decreased, whereas prolactin, adrenocorticotropic hormone (ACTH), cortisol, and growth hormone (GH) increased significantly according to repeatedmeasures analysis of variance (ANOVA) (P<0.05 for all). Compared to controls and T2DM, patients with T1DM exhibited elevated basal GH (P=0.002) and an exaggerated GH response to hypoglycemia (P=0.002), with earlier onset and sustained elevation. In contrast, patients with T2DM showed higher ACTH (P=0.024) and cortisol (P=0.043) levels during hypoglycemia compared to controls and T1DM. Relative to the T1DM group, the T2DM group demonstrated lower testosterone and higher estradiol levels during hypoglycemia (P<0.001 for both).
Conclusion
Distinct diabetes subtypes demonstrate divergent pituitary-adrenal counter-regulatory responses to hypoglycemia, suggesting unique pathogenic mechanisms contributing to glycemic variability. The exaggerated GH response in T1DM may aggravate glucose fluctuations, whereas elevated ACTH and cortisol in T2DM could perpetuate insulin resistance.

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
A Nomogram for End-Stage Renal Disease Prediction in Patients with Type 2 Diabetes Mellitus: A Nationwide Cohort Study in Korea: Inha Jung, Bong-Seong Kim, So Young Park, Da Young Lee, Ji Hee Yu, Ji A Seo, Kyung-Do Han, Nan Hee Kim; Endocrinol Metab. 2026;41(2):245-255. Published online November 12, 2025; DOI: https://doi.org/10.3803/EnM.2025.2570

1,935 View
66 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Despite the rising incidence of end-stage renal disease (ESRD) among individuals with type 2 diabetes mellitus (T2DM) in Korea, no predictive model or nomogram has been developed using a nationwide cohort. In this study, we developed a nomogram to predict the long-term risk of ESRD in patients with T2DM using a large-scale, population-based Korean database.
Methods
Using the Korean National Health Insurance Database, patients with T2DM who underwent health examinations between 2015 and 2016 were assigned as development (n=1,744,277) and validation (n=747,407) cohorts. New ESRD cases were identified using codes for renal replacement therapy. A Cox proportional hazards regression model was used to derive a risk-scoring system, and 13 variables were selected. A risk score nomogram was then created to estimate the risk of ESRD.
Results
In the development cohort, 8,631 patients with T2DM developed ESRD during a follow-up period of 4.8±0.9 years. After multivariable adjustment, significant predictors of ESRD included male sex, current smoking, physical inactivity, low income, low body mass index, hypertension, low-density lipoprotein cholesterol ≥160 mg/dL, chronic kidney disease, insulin use, and longer duration of T2DM. A final nomogram incorporating 13 variables was developed to estimate the individual probability of ESRD. The concordance index for ESRD prediction in the validation cohort was 0.906 (95% confidence interval, 0.9 to 0.912).
Conclusion
This 13-variable nomogram provides a simple tool for identifying patients with T2DM at high risk of ESRD and may aid in early intervention.

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Impact of Glucose Metabolism Status on the Association between Apolipoprotein A-I and Ischemic Risk in Patients with Coronary Artery Disease: A Large-Sample Cohort Study: Kailun Yan, Jiawen Li, Kexin Zhang, Menglu Liu, Pei Zhu, Xiaofang Tang, Deshan Yuan, Yuejin Yang, Runlin Gao, Jinqing Yuan, Xueyan Zhao; Endocrinol Metab. 2025;40(6):904-915. Published online November 7, 2025; DOI: https://doi.org/10.3803/EnM.2025.2407

1,427 View
43 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Apolipoprotein A-I (ApoA-I) is a key cardioprotective lipoprotein. Nevertheless, it remains unclear how ApoA-I relates to ischemic risk across glucose metabolism statuses in patients with coronary artery disease (CAD). This study investigated whether glucose metabolism status influences the association between ApoA-I and ischemic risk in CAD patients.
Methods
This cohort study included 10,724 consecutive CAD patients undergoing percutaneous coronary intervention, who were classified into diabetes mellitus (DM), pre-DM, and normal glucose regulation (NGR) groups. The primary clinical endpoint was major adverse cardiac and cerebrovascular event (MACCE), defined as a composite of all-cause death, myocardial infarction, revascularization, and stroke.
Results
Of the 10,232 patients ultimately included, 2,139 (20.9%) experienced MACCE over 5 years. A significant interaction was observed between ApoA-I levels and glucose metabolism status (P for interaction=0.041). In the DM group, an L-shaped association between ApoA-I and MACCE was found, with lower ApoA-I levels linked to a higher risk of MACCE (P for non-linearity= 0.044). Multivariate Cox regression analysis showed that patients in the lowest quintile of ApoA-I had a 1.327-fold increased risk of MACCE compared to those at the lowest risk (hazard ratio, 1.327; 95% confidence interval, 1.097 to 1.604). However, no significant association was observed in the pre-DM or NGR groups (both P>0.05).
Conclusion
This large-scale, 5-year follow-up study is the first to demonstrate that lower ApoA-I levels are associated with increased MACCE risk in CAD patients with DM, highlighting the potential value of ApoA-I in risk stratification and as a therapeutic target.

Brief Report

Diabetes, obesity and metabolism
Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus: Noboru Kurinami, Masafumi Takada, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Kenji Ashida, Masatoshi Nomura, Hideaki Jinnouchi; Endocrinol Metab. 2025;40(6):1012-1015. Published online October 15, 2025; DOI: https://doi.org/10.3803/EnM.2025.2420

4,025 View
174 Download
1 Web of Science
1 Crossref

Abstract PDF PubReader ePub

Tirzepatide has demonstrated greater efficacy than semaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes mellitus (T2DM). However, the optimal tirzepatide dose following a switch from 1.0 mg of semaglutide remains unclear. This retrospective study included 15 T2DM patients who switched to tirzepatide due to inadequate weight loss. All patients started tirzepatide at 2.5 mg, with escalation to either 7.5 mg (n=10) or 10 mg (n=5). Changes in glycated hemoglobin (HbA1c) and body weight were assessed over a 3-month period. The 10 mg group experienced a significant reduction in HbA1c (−0.7%±0.3%, P<0.01) and a non-significant trend toward weight loss (−6.6±5.4 kg, P=0.07). In contrast, no significant changes were observed in the 7.5 mg group. There were no statistically significant differences between groups. Since 10 mg of tirzepatide significantly improved glycemic control after switching from 1.0 mg of semaglutide, early escalation to 10 mg may be beneficial for patients who respond inadequately to semaglutide.

Citations

Citations to this article as recorded by

Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry
Nicholas P. McCormick, Cristiano S. Moura, Jingyi Zhang, Emily E. Holladay, Fenglong Xie, Tapan Mehta, Joshua F. Baker, Jeffrey R. Curtis
ACR Open Rheumatology.2026;[Epub] CrossRef

Original Articles

Diabetes, obesity and metabolism
Effects of Progranulin Deficiency on Inflammation and Fibrosis in the Kidneys and Liver of Diabetic Mice Fed a High-Fat Diet: Hiroko Sakuma, Maki Murakoshi, Shinji Hagiwara, Terumi Shibata, Yusuke Suzuki, Tomohito Gohda; Endocrinol Metab. 2026;41(1):138-151. Published online September 30, 2025; DOI: https://doi.org/10.3803/EnM.2025.2339

2,485 View
90 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Progranulin (PGRN) is an important regulator of inflammation, insulin resistance, and autophagy. However, the effects of PGRN deficiency on these processes in the kidneys and liver in diabetes remain unclear. In addition, the differential effects of PGRN deficiency and sodium-glucose co-transporter-2 (SGLT2) inhibitors on these organs are unknown.
Methods
Three diabetic mouse models were used: high-fat diet and nicotinamide/streptozotocin-induced diabetic wild-type (WT) and PGRN-knockout (KO) mice (WT-diabetes mellitus [DM] and KO-DM, respectively) and WT-DM mice treated with an SGLT2 inhibitor (tofogliflozin; WT-DM/Tofo).
Results
Despite similar glycemic control in WT-DM/Tofo and KO-DM mice, expression of inflammation- and fibrosis-related genes in the kidneys was highest in WT-DM mice, lower in KO-DM mice, and lowest in WT-DM/Tofo mice. WT-DM/Tofo mice also showed increased anti-microtubule-associated protein 1A/1B-light chain 3B and decreased p62 protein levels compared with KO-DM mice. In contrast, hepatic mRNA levels related to inflammation and fibrosis were improved in both WT-DM/Tofo and KO-DM mice. Moreover, hepatic protein levels of peroxisome proliferator-activated receptor γ (PPARγ) were elevated in both groups compared with WT-DM mice, while those of PPARα were increased in WT-DM/Tofo mice compared with both WT-DM and KO-DM mice.
Conclusion
Kidney inflammation and fibrosis were ameliorated in WT-DM/Tofo mice, but these improvements were limited by autophagy insufficiency in KO-DM mice. Additionally, both WT-DM/Tofo and KO-DM mice demonstrated improved liver inflammation and fibrosis; in the former, this was associated with enhanced fatty acid oxidation via PPARα activation, while in the latter, it appeared to result from improved insulin sensitivity and anti-inflammatory effects through PPARγ activation.

Citations

Citations to this article as recorded by

Effect of Tofogliflozin on Skeletal Muscle Mitochondrial Function in Male Diabetic Mice With Muscle Atrophy
Chiaki Kishida, Maki Murakoshi, Hiroko Sakuma, Terumi Shibata, Yusuke Suzuki, Tomohito Gohda
Journal of the Endocrine Society.2026;[Epub] CrossRef
Progranulin Deficiency Improves Metabolic Stress Yet Falls Short of Sodium-Glucose Cotransporter-2 Inhibition in Autophagy-Linked Renal Protection
Seung-Soon Im
Endocrinology and Metabolism.2026; 41(1): 105. CrossRef
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh
Endocrinology and Metabolism.2025; 40(6): 851. CrossRef

Diabetes, obesity and metabolism
Reduced Sphingosine-1-Phosphate Levels Exacerbate Type 2 Diabetes Mellitus and Associated Complications in a High-Fat Diet Mouse Model: Shih-Chang Hsu, Ching-Lu Chen, Chung Te Liu, Hung-Chieh Lo, Ying-Kuo Liu, Pei-Song Gao, Shau-Ku Huang, Chin-Wang Hsu; Endocrinol Metab. 2026;41(1):108-120. Published online August 5, 2025; DOI: https://doi.org/10.3803/EnM.2025.2360

3,292 View
98 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Type 2 diabetes mellitus (T2DM) is increasingly prevalent and frequently associated with obesity, insulin resistance, nonalcoholic fatty liver disease, and chronic kidney disease. Emerging evidence suggests sphingosine-1-phosphate (S1P), a bioactive sphingolipid, plays a significant role in the pathogenesis of T2DM. This study aimed to investigate how reduced S1P levels impact T2DM development.
Methods
S1P lyase knock-in (S1PL^C317A KI) mice, characterized by reduced S1P levels due to impaired S1P degradation, were compared with wild-type (WT) mice. Both groups were fed a high-fat diet (HFD) to induce T2DM. Parameters including body weight, insulin resistance, blood glucose levels, hepatic fat accumulation, and kidney pathology were evaluated. Next-generation sequencing was employed to identify differentially expressed genes.
Results
S1PL^C317A KI mice exhibited greater body weight, more pronounced insulin resistance, and higher blood glucose levels compared to WT mice on an HFD. Increased hepatic fat deposition and worsened diabetic kidney disease were also observed in KI mice. Sequencing analysis identified 4,656 differentially expressed genes, notably enriched in mitochondrial and bioenergetic pathways, including 133 diabetes-related genes.
Conclusion
Reduced S1P levels exacerbate T2DM symptoms, indicating that therapeutic targeting of S1P pathways may offer promising strategies for treating T2DM and its related complications.

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Early-Onset Dementia Risk Escalates with Diabetes Duration: Insights from a Nationwide Cohort Study: Ji-Hong Park, Sun-Joon Moon, Da Yeon Lee, Ji-Hee Ko, Han Na Jang, Hye-Mi Kwon, Se-Eun Park, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee; Endocrinol Metab. 2026;41(2):235-244. Published online July 17, 2025; DOI: https://doi.org/10.3803/EnM.2024.2287

3,012 View
81 Download
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The prevalence of diabetes mellitus and early-onset dementia (EOD), defined as dementia diagnosed at an age <65 years, is increasing worldwide, with significant socioeconomic implications. We investigated the association between diabetes, prediabetes, and EOD, focusing on the influence of diabetes duration on EOD risk.
Methods
Using the Korean National Health Insurance Service database, we analyzed data from 1,979,509 patients aged 40–60 years who underwent health checkups in 2009. Patients were categorized into five groups: normal, impaired fasting glucose (IFG), newly diagnosed diabetes, diabetes duration <5 years, and diabetes duration ≥5 years. Cox proportional hazard models were used to estimate the adjusted hazard ratios (aHRs) for EOD after adjusting for demographic and clinical covariates.
Results
During the observation period (mean 7.75 years), 8,921 patients with EOD were identified. The diabetes group demonstrated a significantly higher incidence of EOD compared to the normal group (aHR, 1.334; 95% confidence interval [CI], 1.226 to 1.451). EOD risk increased with longer diabetes duration, with the highest risk observed in patients with diabetes ≥5 years (aHR, 1.543; 95% CI, 1.368 to 1.741). No significant difference was observed between the IFG and normal groups (aHR, 0.989; 95% CI, 0.938 to 1.043). Additionally, the hypertension group exhibited a significantly higher incidence of EOD compared to the non-hypertension group (aHR, 1.364; 95% CI, 1.291 to 1.442).
Conclusion
Diabetes is independently associated with increased risk of EOD, and this risk increases with longer diabetes duration. This association remained significant regardless of the presence and duration of hypertension.

Citations

Citations to this article as recorded by

Research Progress on Time in Range as a Predictor of Chronic Complications in Type 2 Diabetes Mellitus
晓雨李
Advances in Clinical Medicine.2026; 16(05): 2100. CrossRef

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Associations of Alcohol Consumption with All-Cause and Cancer Mortalities in Patients with Type 2 Diabetes Mellitus: A Nationwide Population Cohort Study: Da Yeon Lee, Sun-Joon Moon, Kyung-Do Han, Ji-Hee Ko, Han-na Jang, Hye-Mi Kwon, Se-Eun Park, Eun-Jung Rhee, Won-Young Lee; Endocrinol Metab. 2025;40(6):893-903. Published online July 14, 2025; DOI: https://doi.org/10.3803/EnM.2024.2275

4,114 View
95 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To investigate the impact of alcohol consumption on all-cause and cancer mortalities in patients with type 2 diabetes (T2D).
Methods
This nationwide cohort study included Korean patients with T2D aged >20 years from a national health exams cohort (2009 to 2012). Participants were categorized based on alcohol consumption: non, mild (<30 g/day), and heavy drinkers (≥30 g/day). Primary outcomes were all-cause and cancer mortality rates. Cox proportional hazard regression analyses were used to calculate adjusted hazard ratios (aHRs) with a 95% confidence interval (CI) with adjustments for age, sex, body mass index, smoking, exercise, comorbidities, diabetes duration, and medications.
Results
Among 2,642,359 participants (median follow-up, 7.8 years), 57.2%, 32.7%, and 10.1% were non, mild, and heavy drinkers, respectively. Compared to non-drinkers, mild alcohol consumption was associated with reduced all-cause mortality (aHR, 0.81; 95% CI, 0.80 to 0.82) and cancer mortality (aHR, 0.88; 95% CI, 0.86 to 0.89), while heavy drinking increased both all-cause (aHR, 1.06; 95% CI, 1.04 to 1.07) and cancer mortalities (aHR, 1.09; 95% CI, 1.06 to 1.11). Subgroup analyses revealed variations: in chronic kidney disease and older age groups, heavy drinkers showed lower risk of all-cause mortality compared to non-drinkers. Regarding cancer mortality, younger and middle-aged groups showed protective effects of alcohol even for heavy drinkers, while females showed linear association between alcohol consumption and cancer mortality.
Conclusion
This study indicates a J-shaped relationship between alcohol consumption and all-cause and cancer mortality risk in patients with T2D, with variations across subgroups. These findings suggest the need for personalized recommendations considering individual risk factors.

Citations

Citations to this article as recorded by

Alcohol and the endocrine system: A critical review of disruptions, potential mechanisms, and health implications
Patricia E. Molina, Liz Simon
Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
High BMI-attributable female-specific cancers: a comprehensive analysis of the global disease burden and trends from 1990 to 2021 and projections to 2040
Guangming Sun, Junmei Tang, Hao Chen, Yue Zhu, Pan Ren, Hanyue Gan, Wenbin Wu
Frontiers in Oncology.2025;[Epub] CrossRef

Adrenal gland
Deep Learning-Based Adrenal Gland Volumetry for the Prediction of Diabetes: Eu Jeong Ku, Soon Ho Yoon, Seung Shin Park, Ji Won Yoon, Jung Hee Kim; Endocrinol Metab. 2025;40(6):991-1001. Published online June 18, 2025; DOI: https://doi.org/10.3803/EnM.2025.2336

2,863 View
87 Download
1 Web of Science

Abstract PDF Supplementary Material PubReader ePub: Background
The long-term association between adrenal gland volume (AGV) and type 2 diabetes (T2D) remains unclear. We aimed to determine the association between deep learning-based AGV and current glycemic status and incident T2D.
Methods
In this observational study, adults who underwent abdominopelvic computed tomography (CT) for health checkups (2011–2012), but had no adrenal nodules, were included. AGV was measured from CT images using a three-dimensional nnU-Net deep learning algorithm. We assessed the association between AGV and T2D using a cross-sectional and longitudinal design.
Results
We used 500 CT scans (median age, 52.3 years; 253 men) for model development and a Multi-Atlas Labeling Beyond the Cranial Vault dataset for external testing. A clinical cohort included a total of 9708 adults (median age, 52.0 years; 5,769 men). The deep learning model demonstrated a dice coefficient of 0.71±0.11 for adrenal segmentation and a mean volume difference of 0.6± 0.9 mL in the external dataset. Participants with T2D at baseline had a larger AGV than those without (7.3 cm³ vs. 6.7 cm³ and 6.3 cm³ vs. 5.5 cm³ for men and women, respectively, all P<0.05). The optimal AGV cutoff values for predicting T2D were 7.2 cm³ in men and 5.5 cm³ in women. Over a median 7.0-year follow-up, T2D developed in 938 participants. Cumulative T2D risk was accentuated with high AGV compared with low AGV (adjusted hazard ratio, 1.27; 95% confidence interval, 1.11 to 1.46).
Conclusion
AGV, measured using deep learning algorithms, is associated with current glycemic status and can significantly predict the development of T2D.

Diabetes, obesity and metabolism
Fatty Liver Index Dynamics as a Predictor of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus and Non-Cirrhotic Livers: Eun-Hee Cho, Min Gu Kang, Chang Hun Lee, Shinyoung Oh, Chen Shen, Ha Ram Oh, Young Ran Park, Hyun Lee, Jong Seung Kim, Ji Hyun Park; Endocrinol Metab. 2025;40(6):883-892. Published online May 29, 2025; DOI: https://doi.org/10.3803/EnM.2024.2286

3,559 View
120 Download
1 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Type 2 diabetes mellitus (T2DM) is a significant risk factor for hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease; however, surveillance strategies for patients with T2DM, especially without cirrhosis, are inadequate. This study examined whether the fatty liver index (FLI) and its dynamic changes can effectively identify patients with T2DM at increased risk for HCC.
Methods
Data from 92,761 individuals with T2DM aged 40 to 79 who underwent two health screenings (2012 to 2015) were analyzed. The FLI, calculated using waist circumference, body mass index, triglycerides, and gamma-glutamyl transferase, was used to stratify patients by baseline FLI and FLI changes between screenings. HCC cases were identified via International Classification of Diseases codes and reimbursement records (2016 to 2020).
Results
Patients with baseline FLI of 30 to 59.9 had a 1.90-fold higher risk (P<0.01) and those with FLI ≥60 had a 2.94-fold higher risk (P<0.01) of developing HCC compared to those with FLI <30. An increase in FLI from <30 to ≥30 resulted in a 2.10-fold higher risk of HCC (P<0.01), while a reduction in FLI from ≥30 to <30 led to a 0.64-fold lower risk (P=0.03). Protective benefits of FLI reduction took approximately 3 years to manifest.
Conclusion
Baseline and dynamic monitoring of FLI effectively identified HCC risk in T2DM patients with non-cirrhotic livers, supporting early detection and intervention.

Citations

Citations to this article as recorded by

Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease
Emilie K. Mitten, Piero Portincasa, György Baffy
International Journal of Molecular Sciences.2026; 27(7): 3241. CrossRef
Impact of Fatty Liver Index on Cardiovascular Disease and Mortality across Alcohol Consumption Levels in Young Adults
Byung-Hun Han, Joonyub Lee, Hun-Sung Kim, Jae-Hyoung Cho, Kyungdo Han, Seung-Hwan Lee
Endocrinology and Metabolism.2026;[Epub] CrossRef

Diabetes, obesity and metabolism
Current Status of Delay in Injectable Therapy among Type 2 Diabetes Mellitus Patients in South Korea: Multicenter Retrospective Study (2015–2021): Jong Han Choi, Min Kyong Moon, Hae Jin Kim, Kyung Ae Lee, Hyun Jin Kim, Jung Hae Ko, Jae-Seung Yun, Seung-Hyun Ko, Suk Chon, Nam Hoon Kim; Endocrinol Metab. 2025;40(5):727-736. Published online May 29, 2025; DOI: https://doi.org/10.3803/EnM.2024.2280

3,530 View
143 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We aimed to assess the therapeutic inertia associated with injectable therapies and the factors influencing glycemic control following these therapies in patients with type 2 diabetes mellitus (T2DM) in South Korea.
Methods
This multicenter, retrospective cohort study included 2,598 T2DM patients aged 20 to 75 years from 10 referral medical centers in South Korea. These patients had been treated with three or four oral antidiabetic drugs (OADs) and were subsequently initiated on insulin (n=1,942) or glucagon-like peptide-1 receptor agonists (GLP-1RAs, n=656) between January 2015 and December 2021. We analyzed the time to initiation of injectable therapy, changes in glycated hemoglobin (HbA1c), and associations between clinical factors and glycemic control.
Results
At the time of injectable therapy initiation, the mean HbA1c was 9.54%, with insulin users having a higher HbA1c level (9.79%) than GLP-1RA users (8.70%). The mean time from starting 3 or 4 OADs to initiating injectable therapy was 3.19 years: 53.5% of patients had started injectable therapy after 2 years, and 24.2% started after 5 years. Among insulin users, older age (P= 0.004), higher body mass index (P=0.035), and lower HbA1c levels at insulin initiation (P<0.001) were associated with better glycemic control. Among GLP-1RA users, only the HbA1c level at therapy initiation (P<0.001) was a significant factor.
Conclusion
This study highlighted significant delays in initiating injectable therapies, particularly insulin, in T2DM patients in South Korea. Early initiation of injectable therapy may improve long-term glycemic control in these patients.

Citations

Citations to this article as recorded by

Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
Jong Han Choi, Shinae Kang, Soo-Kyung Kim, Won Jun Kim, Ji Min Kim, Jaehyun Bae, Jae-Seung Yun, Eonju Jeon, Young-Eun Kim, Jae Hyun Bae, Hun Jee Choe, Young Min Cho, Seung-Hyun Ko, Sang Yong Kim, Hae Jin Kim, You-Cheol Hwang, Min Kyong Moon, Suk Chon, Seo
Diabetes & Metabolism Journal.2025; 49(6): 1155. CrossRef

Diabetes, obesity and metabolism
Exploring Sex Differences in Type 2 Diabetes via a Male-Dominant Beta-Cell Cluster from Single-Cell Pancreatic Sequencing of Public Datasets: Nguyen Van Anh, Hyo-Wook Gil, Samel Park, Seongho Ryu; Endocrinol Metab. 2025;40(5):706-717. Published online May 19, 2025; DOI: https://doi.org/10.3803/EnM.2025.2297

4,173 View
92 Download
3 Web of Science
4 Crossref

Abstract PDF PubReader ePub

Background
Type 2 diabetes is a complex metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. Although sex differences in type 2 diabetes prevalence, progression, and complications have been reported, the molecular mechanisms underlying these differences remain largely unknown. We aimed to utilize single-cell RNA sequencing to identify a beta-cell cluster that is more prevalent in males than in females and exhibits distinct gene expression patterns, gene set enrichment profiles, and cell-cell communication compared to other clusters.
Methods
FASTQ files from four public datasets were preprocessed, aligned to the human genome (GRCh38), and integrated into a high-quality matrix to mitigate batch effects. We focused on beta-cells from type 2 diabetes patients, performed trajectory inference to identify clusters, and conducted differential gene expression and gene set enrichment analyses. These findings were validated using bulk RNA-seq datasets. Additionally, cell-cell communication analysis was performed to identify ligand-receptor interactions, followed by a sensitivity analysis to assess sex-specific differences.
Results
We identified a male-dominant beta-cell cluster (adjusted P value=4.2×10^–6) that displayed unique gene expression patterns and downregulation of pathways associated with protein metabolism and insulin synthesis. Differentially expressed genes (e.g., interleukin 24 [IL24], regulator of G protein signaling like 1 [RGSL1]) were confirmed through bulk analysis. Moreover, the cluster demonstrated distinct communication patterns with other cell types, underscoring sex-specific differences.
Conclusion
We have identified a male-dominant beta-cell cluster characterized by distinct gene expression, signaling pathways, and cell interactions. These findings provide insights into the pathophysiology of type 2 diabetes and may inform the development of more effective, sex-specific therapeutic strategies in the future.

Citations

Citations to this article as recorded by

Progenitor CD8+ T cells and hyper-Treg crosstalk: a driver of immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma
Suning Huang, Jingwei Yan, Wenqi Liu, Baijun Li
Apoptosis.2026;[Epub] CrossRef
Sex differences in animal models of complex disorders: Affective disorders, type 2 diabetes mellitus and essential hypertension
Mai Abu-Moch, Abed N. Azab, Muhammad Yousef, Galila Agam
Biomedicine & Pharmacotherapy.2026; 198: 119356. CrossRef
Biological sex affects human islet gene expression and mitochondrial function in type 2 diabetes
Sing-Young Chen, Haoning Howard Cen, Charlotte F Chao, Andrew R Pepper, James D Johnson, Elizabeth J Rideout
Endocrinology.2026;[Epub] CrossRef
Exploring Sex-Specific Mechanisms in Type 2 Diabetes Mellitus by Single-Cell Analysis in Pancreatic Islets
Joonyub Lee
Endocrinology and Metabolism.2025; 40(5): 699. CrossRef

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
The Triglyceride-Glucose Index and Risk of End-Stage Renal Disease across Different Durations of Type 2 Diabetes Mellitus: A Longitudinal Cohort Study: Mi-sook Kim, Kyu-Na Lee, Jeongmin Lee, Jeongeun Kwak, Seung-Hwan Lee, Hyuk-Sang Kwon, Jing Hughes, Kyung-Do Han, Eun Young Lee; Endocrinol Metab. 2025;40(5):718-726. Published online May 19, 2025; DOI: https://doi.org/10.3803/EnM.2024.2271

6,475 View
109 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the association between the triglyceride-glucose (TyG) index, a marker of insulin resistance, and the risk of end-stage renal disease (ESRD) in individuals with type 2 diabetes mellitus (T2DM), focusing on variations by diabetes duration.
Methods
We analyzed 1,219,148 Korean adults with T2DM from National Health Insurance Service data who underwent biennial health evaluations (2015 to 2016). ESRD was defined using specific procedural codes (V codes), and Cox proportional hazard models were employed to estimate hazard ratios (HRs) for ESRD across TyG index quartiles and diabetes duration categories, adjusting for various confounders.
Results
Over 6,967,381 person-years of follow-up, 7,548 participants developed ESRD. Higher TyG index quartiles were independently associated with increased risk of ESRD, which was more pronounced with longer diabetes duration. The adjusted HR for ESRD in the highest TyG quartile (Q4) compared to the lowest quartile (Q1) was 1.235 (95% confidence interval [CI], 0.995 to 1.533) in new-onset diabetes, and 1.592 (95% CI, 1.465 to 1.730) in those with diabetes for ≥10 years. Compared to the lowest TyG quartile in new-onset diabetes, the adjusted HR for ESRD in the highest quartile with diabetes duration ≥10 years increased to 10.239 (95% CI, 8.440 to 12.422). Subgroup analysis revealed that a higher TyG index consistently increased the risk of ESRD, with stronger associations observed in younger individuals and those without comorbidities.
Conclusion
The TyG index is a significant predictor of ESRD in T2DM, particularly in those with prolonged diabetes duration. Targeting insulin resistance early may mitigate the risk of ESRD in this population.

Citations

Citations to this article as recorded by

Association between TYG-BMI index and asthma in adults over 45 years of age: analysis of Global Burden of Disease 2021, China Health and Retirement Longitudinal Study, and National Health and Nutrition Examination Survey data
Zhuolin Qin, Longqian Li, Cheng Wang
Journal of Asthma.2026; 63(2): 214. CrossRef
The Association Between the Triglyceride–Glucose Index and the Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study
Munther S. Momani, Raneem Dalaeen, Dia Sarhan, Zaid Sarhan, Suhib Awamleh, Yazan M. Momani, Omar Abu Farsakh
Life.2026; 16(2): 345. CrossRef
Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study
Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim
Diabetologia.2026; 69(7): 1858. CrossRef

Review Article

Diabetes, obesity and metabolism
Prevalence and Current Status of Cardiometabolic Risk Factors in Korean Adults Based on Fact Sheets 2024: Eun-Jung Rhee; Endocrinol Metab. 2025;40(2):174-184. Published online April 24, 2025; DOI: https://doi.org/10.3803/EnM.2025.2398

5,867 View
119 Download
7 Web of Science
8 Crossref

Abstract PDF PubReader ePub

Korea has entered ‘super-aged’ society in 2025 with the proportion of people 65 years or older exceeding 20% as of the end of the year 2024. The health burden of cardiovascular diseases increases with age, and the increasing prevalence of cardiovascular risk factors, such as obesity, hypertension, diabetes mellitus, and dyslipidemia, may be linked to increased population-level cardiovascular risk. According to data from 2022, the overall prevalence of obesity reached 38.4%, marking a continued upward trend, based on National Health Insurance medical checkup data. In the combined data of 2021 to 2022, the prevalence of diabetes was 15.5% in Koreans older than 30 years according to the Diabetes Fact Sheet 2024 published by the Korean Diabetes Association, based on data from the Korean National Health and Nutrition Examination Survey. The prevalence of hypertension in the total population of Korea in 2022 was 30% according to the Korean Hypertension Fact Sheet produced by the Korean Society of Hypertension. Lastly, the prevalence of dyslipidemia in 2022 was 40.9% according to the Dyslipidemia Fact Sheet published by the Korean Society of Lipid and Atherosclerosis. In this article, I would like to review the prevalence and current management of cardiovascular risk factors in Korea according to the fact sheets released by various associations in 2024.

Citations

Citations to this article as recorded by

High incidence of eating disorders in individuals with type 2 diabetes and their association with cardiovascular and mortality risks
So Hyun Cho, Seohyun Kim, Rosa Oh, Ji Yoon Kim, Myunghwa Jang, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim
Diabetologia.2026; 69(3): 653. CrossRef
Epidemiology and characteristics of obesity in Koreans based on the 2024 Obesity Fact Sheet
Eun-Jung Rhee
Journal of the Korean Medical Association.2026; 69(1): 4. CrossRef
Association Between Vitamin D Deficiency and Glycemic, Lipid, and Adiposity Markers in Older Adults: A Nationally Representative Study
Yong-Joon Kim, Kyeongmin Jang
Metabolites.2026; 16(4): 270. CrossRef
2024 Cardio-cerebrovascular disease fact sheet in Korea
Kyungdo Han, Jin-Hyung Jung, Sang-Suk Choi, Seung-Hyun Ko
Cardiovascular Prevention and Pharmacotherapy.2025; 7(3): 85. CrossRef
Study of diastolic dysfunction in diabetic patients and its correlation with microalbuminuria
Rishibha Kaushik, B. P. Priyadarshi, Lalit Kumar, Yuvraj Gulati, Madhuri Priyadarshi, S. K. Sinha
International Journal of Advances in Medicine.2025; 12(5): 462. CrossRef
Relationship Between Oral Function and Social Participation Among Community-Dwelling Older Adults: An Observational Cross-Sectional Study
Mayu Takeda, Yuhei Matsuda, Takafumi Abe, Kazumichi Tominaga, Hisaaki Saito, Jun Shimizu, Norikuni Maeda, Ryouji Matsuura, Yukio Inoue, Yuichi Ando, Shozo Yano, Minoru Isomura, Takahiro Kanno
Healthcare.2025; 13(18): 2271. CrossRef
Cardiometabolic Risk Factors Among Adults in a Rural Amazonian Peruvian Population
Miguel A. Arce-Huamani, Gustavo A. Caceres-Cuellar, Anyela Y. Guevara-Paz, Cleofe R. Lopez-Quispe, Abhely K. Barzola-Blancas, Valeria A. Cespedes-Atto, Catherine G. Acosta-Celis, Katherine Pérez-Acuña, Williams Carrascal-Astola, J. Smith Torres-Roman
Medicina.2025; 61(12): 2206. CrossRef
Longitudinal associations of serum Irisin and adiponectin with incident metabolic syndrome in middle-aged and older adults over three years
Yejin Kim, Hong Ji Song, Dong-Hyun Kim, Jin-Young Jeong, Kyung Hee Park, Jwa-Kyung Kim, Hye-Mi Noh
Scientific Reports.2025;[Epub] CrossRef

Original Article

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
The Severity of Diabetes and the Risk of Diabetic Foot Amputation: A National Cohort Study: Jin Yu, Ji-Hyun Kim, Bongseong Kim, Kyungdo Han, Seung Hwan Lee, Mee Kyoung Kim; Endocrinol Metab. 2025;40(4):574-582. Published online April 15, 2025; DOI: https://doi.org/10.3803/EnM.2024.2266

6,711 View
172 Download
6 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study aimed to assess whether markers of diabetes severity could serve as predictors for foot amputation risk among patients with type 2 diabetes mellitus.
Methods
We analyzed data from the nationally representative Korean National Health Insurance System database, tracking 2,544,077 patients with type 2 diabetes mellitus who participated in routine health check-ups between 2009 and 2012, with followup extending through the end of 2018. The parameters used to define the diabetes severity score encompassed diabetes duration, insulin usage, the number of oral glucose-lowering medications, the presence of chronic kidney disease, diabetic retinopathy, and cardiovascular disease. Each factor was assigned one point, yielding a cumulative severity score ranging from 0 to 6.
Results
The risk of diabetic foot amputation was predominantly predicted by insulin therapy, diabetic retinopathy, and a prolonged duration of diabetes. The hazard ratios for foot amputation increased with the severity score as follows: 2.31 (95% confidence interval [CI], 2.15 to 2.47) for a score of 1, 4.73 (95% CI, 4.42 to 5.07) for a score of 2, 8.86 (95% CI, 8.24 to 9.53) for a score of 3, 16.95 (95% CI, 15.60 to 18.4) for a score of 4, 23.98 (95% CI, 21.25 to 27.05) for a score of 5, and 37.87 (95% CI, 28.93 to 49.57) for a score of 6.
Conclusion
Specific markers of advanced diabetes effectively identified patients at an elevated risk for diabetic foot amputation.

Citations

Citations to this article as recorded by

Costos directos y determinantes de las amputaciones en pacientes diabéticos en un hospital de Nicaragua en el año 2024.
Sidley Irania Hurtado Alvarado, Sheila Karina Valdivia Quiroz
Revista Multidisciplinaria Voces de América y el Caribe.2026; 3(1): 12. CrossRef
Nationwide Big Data Studies of Endocrine Diseases Using the Korean National Health Information Database: Research Trends and Standardization of Operational Definitions
Sun Wook Cho, Jung Hee Kim, Kyoung Jin Kim, Beom-Jun Kim, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2026; 41(1): 86. CrossRef
Cardiovascular outcomes with thiazolidinediones and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus undergoing peripheral artery revascularization
Ji Woong Roh, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok-Jae Heo, Deok-Kyu Cho, Jinkwon Kim
Diabetes Research and Clinical Practice.2026; 236: 113281. CrossRef
Diabetes progression and its association with fracture risk in type 2 diabetes
Bongsung Kim, Kyu-Na Lee, Kyungdo Han, Mee Kyoung Kim
Osteoporosis International.2026;[Epub] CrossRef
Development, validation, and pilot implementation of a prognostic model to predict future foot complications among people with diabetes recently discharged from hospital
Surain B. Roberts, Anne Löffler, Dhanesh Ramachandram, Javier Garay-Fernandez, Maia Norman, Conrad Pow, Fahad Razak, Amol A. Verma, Charles de Mestral
Journal of Clinical Epidemiology.2026; 195: 112295. CrossRef
Hemoglobin-albumin-lymphocyte-platelet score associated with diabetic foot severity, unlike modified systemic immune-inflammatory index and modified systemic inflammatory response index
Weiyu Pan, Zhaoyuan Nie, Qizhi Tang, Ling Zhao
Frontiers in Endocrinology.2026;[Epub] CrossRef
Diabetes Progression and Its Impact on Kidney Cancer Risk: Insights From a Longitudinal Korean Cohort Study
Jin Yu, Bongseong Kim, Kyungdo Han, Mee Kyoung Kim
The Journal of Clinical Endocrinology & Metabolism.2025; 111(1): e125. CrossRef
Association of high-density lipoprotein-related inflammatory indicators with diabetic foot ulcer in patients with diabetes: a population-based study
Renhe Deng, Ruyi Tao, Huiyi Luo, Yueqi Gu, Mengyu Yang, Chaoqi Yin
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef

Review Article

Diabetes, obesity and metabolism
Advances in Continuous Glucose Monitoring: Clinical Applications: So Yoon Kwon, Jun Sung Moon; Endocrinol Metab. 2025;40(2):161-173. Published online April 8, 2025; DOI: https://doi.org/10.3803/EnM.2025.2370

32,217 View
813 Download
18 Web of Science
28 Crossref

Abstract PDF PubReader ePub

Continuous glucose monitoring (CGM) has revolutionized diabetes management, significantly enhancing glycemic control across diverse patient populations. Recent evidence supports its effectiveness in both type 1 and type 2 diabetes management, with benefits extending beyond traditional glucose monitoring approaches. CGM has demonstrated substantial improvements in glycemic control across multiple metrics. Studies report consistent glycosylated hemoglobin reductions of 0.25%–3.0% and notable time in range improvements of 15%–34%. CGM effectively reduces hypoglycemic events, with studies reporting significant reductions in time spent in hypoglycemia. CGM also serves as an educational tool for lifestyle modification, providing real-time feedback that helps patients understand how diet and physical activity affect glucose levels. While skin-related complications remain a concern, technological advancements have addressed many initial concerns. High satisfaction rates and long-term use suggest that device-related issues are manageable with proper education and support. Despite high initial costs, CGM’s prevention of complications and hospitalizations ultimately reduces healthcare expenditures. With appropriate training and support, CGM represents a transformative technology for comprehensive diabetes care.

Citations

Citations to this article as recorded by

Glycemic Control Practices in Intensive Care Units: A National Survey Study
Zeynep Irmak Kaya, Serdar Efe
Cerasus Journal of Medicine.2026; 3(2): 132. CrossRef
Advancements in Continuous Glucose Monitoring: a Revolution in Diabetes Management
Kondreddy Vinod Kumar, Kamal Raj Yerraguntla, Maruthi Prasad Jenne, Abhilash Gadi, Akhila Sepoori, Anusha Gunda, Madhu Sri Gudivada
Biomedical Materials & Devices.2026; 4(3): 3126. CrossRef
Advancements in glucose biosensors: Innovations for wearable and real-time monitoring
Reetu Singh, Priyanshu Nema, Arpana Purohit, Satyamshyam Vishwakarma, Shyamji Tantuway, Pradhumn Namdeo, Ajay Kumar, Vandana Soni, Sushil Kumar Kashaw
Talanta.2026; 299: 129045. CrossRef
Continuous glucose monitoring in high-risk individuals
Zhiyue Chen, Yinbei Zhang, Lin Sun, Weiying Guo
Clinica Chimica Acta.2026; 580: 120733. CrossRef
Scoping review of subcutaneous glucose monitoring techniques
Eva Hrubá, Jan Kubíček, Martin Augustynek
Measurement.2026; 261: 119940. CrossRef
Continuous Glucose Monitoring for Pancreatogenic Diabetes After Total Pancreatectomy
Young Jae Cho, Inhyuck Lee, Yoon Soo Chae, Go‐Won Choi, Younsoo Seo, Youngmin Han, Hye‐sol Jung, Wooil Kwon, Joon Seong Park, Jin‐Young Jang
Journal of Hepato-Biliary-Pancreatic Sciences.2026; 33(3): 208. CrossRef
Use of continuous glucose monitoring in non-intensively managed type 2 diabetes: a Saudi Arabian consensus
Mohammed Almehthel, Abdulghani Al-Saeed, Fahad Al-Sabaan, Faisal Al-Malky, Hawazen Zarif, Lamya Al-Zubaidi, Mohammed E. Al-Sofiani, Omar Abdulaal, Reem Al Argan, Saud Al Sifri, Turki Al-Harbi, Raed Aldahash
Frontiers in Endocrinology.2026;[Epub] CrossRef
Wearable microneedle sensors for continuous interstitial fluid monitoring
Junghyun Cho, Heeju Son, Jayoung Kim, Hyun Seok Song, Wonryung Lee
Biosensors and Bioelectronics.2026; 297: 118385. CrossRef
Efficacy of an AI-Enabled Low Glucose Prediction: A Pooled Performance Analysis With Capillary Blood Glucose as Ground Truth
Timor Glatzer, Ajandek Peak, Eemeli Leppäaho, Patrick Lustenberger, Pau Herrero, Magí Andorrà, Ellen van Maren
Journal of Diabetes Science and Technology.2026;[Epub] CrossRef
Respiratory Signal Processing and Analysis Using Flexible Capacitive Sensor Data
Bernardo A. Vicente, Raquel Sebastião, Alda Marques, Vitor Sencadas
Advanced Materials Technologies.2026;[Epub] CrossRef
Toward continuous and non-invasive monitoring: a scoping review of in vitro blood glucose devices from electrochemistry to optics and micro-system integration
Wanmeng Wang, Chongyu Liu, Peiwen Lin, Suo Li, Yongchao Yao, Zhuqing Wang, Wenchuang (Walter) Hu
Journal of Materials Chemistry B.2026; 14(11): 3383. CrossRef
Biobanking in der Inneren Medizin
Denise Zwanziger
Die Innere Medizin.2026; 67(4): 418. CrossRef
EMERGING DIGITAL TECHNOLOGIES IN MONITORING ENDOCRINE DISORDERS: CONTINUOUS GLUCOSE MONITORING SYSTEMS AND ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME
Aleksandra Ćwirko-Godycka, Nikola Murawska, Michalina Chodór, Aleksandra Tomaszewska, Kinga Karczewska, Sonia Mojzyk, Maciej Kokoszka, Aleksandra Mierniczek, Natalia Dymel, Ryszard Feret
International Journal of Innovative Technologies in Social Science.2026;[Epub] CrossRef
Changes in Continuous Glucose Monitoring Metrics During the Initial Phase of a Korean Medicine–Based Weight Reduction Program: A Retrospective Observational Study
Minwoo Bang, Suyong Shin, Jungsang Kim, Minwhee Kang, Donghun Lee, Junho Kim, Chunghee Kim, Jiyoung Son, Seonghyeon Jeon, Byungsoo Kang
Journal of Korean Medicine.2026; 47(1): 87. CrossRef
Long-term impact of continuous glucose monitoring on glycemic and metabolic control in type 1 diabetes: A three-year real-world evaluation
Ayman Al Hayek, Wael M. Al Zahrani, Haifa F. AlOtaibi, Jehad Y. Saleh, Mohammed A. Al Dawish
Primary Care Diabetes.2026; 20(3): 326. CrossRef
Non-enzymatic sweat sensors for pediatric continuous glucose monitoring: a systematic review of engineering readiness and the cost-accuracy trade-off
Oluwanifemi Temiloluwa Bolaji, Emmanuel Dominic Ephraim, Olumhense Benedict Adoghe, Deborah Daramola, Emmanuel Francis Kibuebu
BMC Biomedical Engineering.2026;[Epub] CrossRef
Identifying Actionable Glucose Patterns in Type 1 and Type 2 Diabetes Using Continuous Glucose Monitoring and Algorithmic Pattern Recognition
Timor Glatzer, Ajandek Peak, Eemeli Leppäaho, Patrick Lustenberger, Pau Herrero, Magí Andorrà, Ellen van Maren
Journal of Diabetes Science and Technology.2026;[Epub] CrossRef
The Current Landscape of Remote Patient Monitoring Regarding Diabetes Mellitus and Hypoglycemia: Protocol for a Scoping Review
Mathew J Stephen, Baylor Akhavan, Melinda B Chu, Kavita Batra, Roberto Sagaribay
JMIR Research Protocols.2026; 15: e88197. CrossRef
Prehospital identification of hypoglycemia-induced seizure using a smartphone-linked continuous glucose monitoring application
Kenji Harada, Yuji Okazaki, Toshihisa Ichiba
The American Journal of Emergency Medicine.2026; 107: 13. CrossRef
Advanced Drug Delivery Approaches for Antidiabetic Agents: Strategies to Enhance Bioavailability, Efficacy, and Patient Compliance
H G Srusti, K Darshini , K V Poorvika , Bramhotri Rout
Journal of Drug Delivery and Therapeutics.2026; 16(5): 182. CrossRef
Use of technology and AI tools in type 2 diabetes
Jothydev Kesavadev, Mohamed Abdul Khader M, Anjana Basanth
Best Practice & Research Clinical Endocrinology & Metabolism.2026; : 102130. CrossRef
Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use
Satish K. Garg, Halis K. Akturk, Samita Garg, Roy W. Beck, Natalie J. Bellini, Petter Bjornstad, Anders L. Carlson, Jim Carroll, Kelly Close, Christophe De Block, Klemen Dovc, Gregory P. Forlenza, Francesco Giorgino, Julie Heverly, Irl B. Hirsch, Mareda L
Diabetes Technology & Therapeutics.2026;[Epub] CrossRef
Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria in type 1 diabetes: A cross-sectional study
Ji Yoon Kim, Seohyun Kim, Sang Ho Park, Jin A Lee, So Hyun Cho, Rosa Oh, Myunghwa Jang, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin
Diabetes Research and Clinical Practice.2025; 226: 112325. CrossRef
SMART CARE FOR DIABETES: INTEGRATING TECHNOLOGY AND LIFESTYLE FOR BETTER OUTCOMES
Aleksandra Maciejczyk, Katarzyna Krupa, Weronika Głowacz, Janusz Świeczkowski-Feiz
International Journal of Innovative Technologies in Social Science.2025;[Epub] CrossRef
Identification of clinically meaningful automatically detected postprandial glucose excursions in individuals with type 1 diabetes using personal continuous glucose monitoring
Sang Ho Park, Rosa Oh, Seohyun Kim, Seung Hee Yang, Hanna Lee, Ji Yoon Kim, So Hyun Cho, Soojin Park, Gyuri Kim, Jae Hyeon Kim, Sang–Man Jin
Diabetes Research and Clinical Practice.2025; 229: 112951. CrossRef
Bridging the digital divide: student-led literacy initiatives in diabetes management
Pedro Almeida Moyano, Mohammed Raddaoui, Andrea de Barros Coscelli Ferraz, Gustavo José Martiniano Porfírio, Luciana Aparecida Campos, Ovidiu Constantin Baltatu
Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol
Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin
Endocrinology and Metabolism.2025;[Epub] CrossRef
Evolution and Future of Glucose Monitoring: From Blood Glucose Meters to Continuous Systems and Their Projected Impact in the Middle East and North Africa (MENA) Region
Omar Darkhabani, Abdalla Ahmed
Cureus.2025;[Epub] CrossRef

Original Articles

Diabetes, obesity and metabolism
Discrepancies in Dapagliflozin Response in Terms of Glycemic Control and Body Weight Reduction: Ji Eun Jun, Kyoung-Ah Kim, Nan-Hee Kim, Kwan-Woo Lee, In-Kyung Jeong, on Behalf of the BEYOND Investigators; Endocrinol Metab. 2025;40(2):278-288. Published online March 19, 2025; DOI: https://doi.org/10.3803/EnM.2024.2142

5,973 View
154 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces hyperglycemia and obesity by inhibiting renal glucose reabsorption. This post hoc study evaluated clinical factors influencing patient response to dapagliflozin.
Methods
The analysis focused on patients treated with dapagliflozin (10 mg/day for 52 weeks) within the randomized, double-blind, parallel-group BEYOND trial. Adequate glycemic control (GC) was defined as a reduction in glycated hemoglobin (HbA1c) of ≥ 1.0% or the achievement of an HbA1c level <7.0% at week 52. Significant weight loss (WL) referred to a reduction in body weight of ≥3.0% at week 52. Participants were classified into four groups based on their GC and WL responses: GC+/WL+, GC+/WL−, GC−/WL+, and GC−/WL−.
Results
Among dapagliflozin recipients (n=56), at 52 weeks, HbA1c had decreased by 1.0%±0.8% from baseline, while body weight had declined by 2.4±3.1 kg. Overall, 69.6% of participants achieved GC+, and 57.1% achieved WL+. Male sex and shorter diabetes duration were significantly associated with achieving GC+. Conversely, higher estimated glomerular filtration rate was significantly linked to WL+. The only factor significantly associated with both GC+ and WL+ was shorter diabetes duration (odds ratio, 0.81; 95% confidence interval, 0.68 to 0.97; P=0.023). The GC+ and WL+ groups exhibited favorable responses beginning soon after dapagliflozin therapy was initiated. Furthermore, HbA1c decline was more strongly associated with reduction in visceral fat than with WL.
Conclusion
A short duration of diabetes and early response to treatment appear to represent key factors in maximizing the benefits of dapagliflozin for blood glucose and weight management.

Citations

Citations to this article as recorded by

Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
A Pre‐Post Assessment of Blood Glucose Control Following Pharmacist‐Led Professional Continuous Glucose Monitoring in Rhode Island Primary Care Practices
Kelley Doherty Sanzen, Natalya S. Salganik, Susanne M. Campbell, Carolyn A. Karner, Pano M. Yeracaris, Stephen J. Kogut
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.2026;[Epub] CrossRef
Identification of IL18/IL18R1 signaling as a predictive biomarker of SGLT2 inhibitor efficacy in type 2 diabetes
I-Jou Teng, Chien-Hsing Lee, Ying-Chen Chen, Sheng-Chiang Su, Chieh-Hua Lu, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Ming-Hsun Lin, Hsin-Ya Liu, Feng-Chih Kuo
iScience.2025; 28(10): 113594. CrossRef

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Association between the Triglyceride-Glucose Index and Cardiovascular Risk and Mortality across Different Diabetes Durations: A Nationwide Cohort Study: Jeongeun Kwak, Kyung-Do Han, Eun Young Lee, Seung-Hwan Lee, Dong-Jun Lim, Hyuk-Sang Kwon, Jeongmin Lee; Endocrinol Metab. 2025;40(4):548-560. Published online March 5, 2025; DOI: https://doi.org/10.3803/EnM.2024.2205

7,110 View
259 Download
9 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We aimed to assess the association between triglyceride-glucose (TyG) index and cardiovascular disease (CVD) risk and mortality in a large cohort of diabetes patients.
Methods
A retrospective cohort study of 1,090,485 participants from the Korean National Health Insurance Service database was conducted. Participants were stratified into TyG quartiles.
Results
Higher TyG index quartiles were significantly associated with an increased CVD risk and mortality risk. In fully adjusted models, participants in the highest TyG quartile (Q4) had an 18% higher risk of CVD (hazard ratio [HR], 1.18; 95% confidence interval [CI], 1.13 to 1.23) and a 16% higher risk of mortality (HR, 1.16; 95% CI, 1.11 to 1.23) compared to those in the lowest quartile (Q1). The association was particularly pronounced in patients with fasting glucose ≥126 mg/dL (CVD [HR, 1.33; 95% CI, 1.29 to 1.37], mortality [HR, 1.23; 95% CI, 1.20 to 1.26]; P for interaction <0.001). Patients with a diabetes duration of ≥10 years showed the strongest association between the TyG index and CVD risk (HR, 1.44; 95% CI, 1.38 to 1.50), while the mortality risk was particularly elevated in those with a diabetes duration of less than 5 years (HR, 1.23; 95% CI, 1.18 to 1.30). Subgroup analyses revealed stronger associations between TyG index and CVD risk in younger participants, non-obese individuals, and non-smokers.
Conclusion
The TyG index is a significant predictor of CVD and mortality in diabetic patients, particularly in those with poor glycemic control or longer disease duration.

Citations

Citations to this article as recorded by

Preoperative triglyceride–glucose index as a metabolic predictor of surgical site infection after posterior lumbar fusion
Yu Hua, Shaoxing Li, Yuan Jiang, Jinwang Liu
Journal of Orthopaedic Surgery.2026;[Epub] CrossRef
Combined effect of triglyceride-glucose index and glucose disposal rate on cardio-cerebrovascular disease
Hongfei Yang, Chao Sun, Ya Li, You Zhou, Rui Wang, Yingxue Li, Marwan Salih Al-Nimer
PLOS One.2026; 21(2): e0342154. CrossRef
The association between insulin resistance indices and the occurrence of major adverse cardiovascular events in patients with premature myocardial infarction: a prospective cohort study
Yu Zhou, Yuhang Wang, Jingxi Chen, Lai Jiang, Ran Chu, Weiwei Tian, Jiaxin Wang, Yin Liu, Jing Gao
Frontiers in Nutrition.2026;[Epub] CrossRef
Current evidence on lipid ratios for cardiovascular risk assessment in diabetes: A review
E. Carretero-Anibarro, D. Orozco-Beltran
Primary Care Diabetes.2026; 20(3): 292. CrossRef
Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study
Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim
Diabetologia.2026; 69(7): 1858. CrossRef
Analysis of the prevalence of dyslipidemia in early-onset schizophrenia patients and its correlation with clinical characteristics
Kehuang Li, Zhiwei Liu, Liang Sun, Jingjing Zhang, Xinglong Yin, Zhaokun Zhang, Changjie Cao
Frontiers in Psychiatry.2026;[Epub] CrossRef
Exploring the relationship between triglyceride-glucose index and peripheral neuropathy in Nigerian patients with type 2 diabetes: a comparison with other metabolic markers
Blessing Kenechi Myke-Mbata, Bruno Basil, Izuchukwu Nnachi Mba, Terna Gav Ambrose
International Journal of Research in Medical Sciences.2026; 14(5): 1812. CrossRef
The Triglyceride-Glucose Index: A Practical Tool for Enhanced Cardiovascular Risk Stratification in Type 2 Diabetes
Jang Won Son
Endocrinology and Metabolism.2025; 40(4): 545. CrossRef
The association between triglyceride-glucose index and all-cause/cardiovascular mortality in patients with different glucose metabolism statuses
Jiajun Liu, Jinhua Kang, Pengpeng Liang, Zhangxiao Song, Guiyun Li, Xueshan Jin, Hongyan Wu
Cardiovascular Diabetology.2025;[Epub] CrossRef
Standardized Triglyceride-Glucose and Plasma Atherogenic Indices as Predictors of Diabetic Nephropathy and Coronary Artery Disease in Patients with Type 1 Diabetes Mellitus
Nazif Yalçın, Nizameddin Koca
European Journal of Therapeutics.2025; 32(1): 1. CrossRef

Diabetes, obesity and metabolism
Prevalence of Mortality and Vascular Complications in Older Patients with Diabetes in Korea: Kwang Joon Kim, Jeongmin Lee, Yang Sun Park, Yong-ho Lee, Kyeong Hye Park, Hee-Won Jung, Chang Oh Kim, Man Young Park, Hun-Sung Kim, Bong-Soo Cha; Endocrinol Metab. 2025;40(3):448-458. Published online February 18, 2025; DOI: https://doi.org/10.3803/EnM.2024.2173

4,988 View
116 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the prevalence of diabetes mellitus (DM) and impaired fasting glucose, as well as their management and comorbidities among older Korean adults.
Methods
Data from 269,447 individuals aged 65 years and older from the Korean National Health Insurance Service between 2000 and 2019 were analyzed to evaluate trends in DM prevalence, healthcare utilization, mortality, and complications.
Results
Among 269,447 individuals, 18.6% (n=50,159/269,447) were diagnosed with DM and 27.0% (n=72,670/269,447) had impaired fasting glucose. The DM group had the highest body mass index, waist circumference, and prevalence of current smokers (P<0.001) but not the highest hypertension prevalence. From 2010 to 2019, the prevalence of DM and impaired fasting glucose increased from 15.5% to 21.9% and from 26.0% to 30.6%, respectively. Cancer-related mortality in DM was 1.15 times higher than in those with normal glucose tolerance (P<0.001), and cardiovascular disease-related mortality was 1.32 times higher (P<0.001); all mortalities were higher in female participants. Myocardial infarction (hazard ratio [HR], 1.34; P<0.001), stroke (HR, 1.24; P<0.001), and heart failure (HR, 1.13; P<0.001) were significantly higher in those with DM.
Conclusion
This is the first study to investigate the prevalence of DM and related complications in older individuals based on longterm representative data in Korea. These results highlight the necessity for targeted interventions to enhance management and outcomes in this population.

Citations

Citations to this article as recorded by

Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study)
Sangmo Hong, Won J. Kim, Sungrae Kim, Jung H. Park, Eun S. Kang, Min K. Moon, Jae T. Kim, Ji‐Oh Mok, Ki Y. Lee, Cheol‐Young Park, Chang B. Lee
Diabetes, Obesity and Metabolism.2026; 28(2): 906. CrossRef

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Time to Insulin Therapy and Severe Hypoglycemia in Korean Adults Initially Diagnosed with Type 2 Diabetes: A Nationwide Study: You-Bin Lee, Kyungdo Han, Bongsung Kim, So Hee Park, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim, Sang-Man Jin; Endocrinol Metab. 2025;40(3):421-433. Published online February 4, 2025; DOI: https://doi.org/10.3803/EnM.2024.2082

4,203 View
99 Download

Abstract PDF Supplementary Material PubReader ePub: Background
We examined the distribution of time to insulin therapy (TIT) post-diabetes diagnosis and the hazard of severe hypoglycemia (SH) according to TIT in Korean adults initially diagnosed with type 2 diabetes (T2D) and who progressed to insulin therapy.
Methods
Using data from the Korean National Health Insurance Service (2002 to 2018), we selected adult incident insulin users (initially diagnosed as T2D) who underwent health examinations between 2009 and 2012. The hazards of SH, recurrent SH, and problematic hypoglycemia were analyzed according to groups categorized using the TIT and clinical risk factors for SH (TIT ≥5 years with risk factors, TIT ≥5 years without risk factors, 3 ≤TIT <5 years, 1 ≤TIT <3 years, and TIT <1 year).
Results
Among 41,637 individuals, 14,840 (35.64%) and 10,587 (25.43%) initiated insulin therapy within <5 and <3 years postdiabetes diagnosis, respectively. During a median 6.53 years, 3,406 SH events occurred. Compared to individuals with TIT ≥5 years and no risk factor for SH, individuals with TIT <3 years had higher outcome hazards in a graded manner (adjusted hazard ratio [95% confidence intervals] for any SH: 1.117 [0.967 to 1.290] in those with 3 ≤TIT <5 years; 1.459 [1.284 to 1.657] in those with 1 ≤ TIT <3 years; and 1.515 [1.309 to 1.754] in those with TIT <1 year). This relationship was more pronounced in the non-obese subpopulation.
Conclusion
Among adults who progressed to insulin therapy after being diagnosed with T2D, a shorter TIT was not uncommon and may predict an increased risk of SH, particularly in non-obese patients.

Review Article

Diabetes, obesity and metabolism
Evolving Characteristics of Type 2 Diabetes Mellitus in East Asia: Joonyub Lee, Kun-Ho Yoon; Endocrinol Metab. 2025;40(1):57-63. Published online January 15, 2025; DOI: https://doi.org/10.3803/EnM.2024.2193

8,497 View
218 Download
12 Web of Science
13 Crossref

Abstract PDF PubReader ePub

In East Asians, type 2 diabetes mellitus (T2DM) is primarily characterized by significant defects in insulin secretion and comparatively low insulin resistance. Recently, the prevalence of T2DM has rapidly increased in East Asian countries, including Korea, occurring concurrently with rising obesity rates. This trend has led to an increase in the average body mass index among East Asian T2DM patients, highlighting the influence of insulin resistance in the development of T2DM within this group. Currently, the incidence of T2DM in Korea is declining, which may indicate potential adaptive changes in insulin secretory capacity. This review focuses on the changing epidemiology of T2DM in East Asia, with a particular emphasis on the characteristics of peak functional β-cell mass.

Citations

Citations to this article as recorded by

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
Da Hea Seo, Kyung Wan Min, Ho Sang Sohn, Sang Yong Kim, In‐Kyung Jeong, Cheol‐Young Park, Kun‐Ho Yoon, So Hun Kim, Bong‐Soo Cha
Diabetes, Obesity and Metabolism.2026; 28(1): 728. CrossRef
A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes
Kenji Ohwaki, Chino Nakamura, Risa Nasu, Kazumasa Takenouchi, Tetsuaki Hirase
Journal of Diabetes Investigation.2026; 17(2): 205. CrossRef
Association between the triglyceride-glucose index and risk of type 2 diabetes mellitus and the mediating effect of BMI: a comparative analysis in Chinese and Japanese populations
Yuxian Chen, Haiyong Zeng, Ziqi Luo, Haofei Hu, XinYu Wang
Frontiers in Endocrinology.2026;[Epub] CrossRef
Anti-Diabetic Potential of Corn (Zea mays L.) Silk: A Systematic Review and Meta-Analysis of Preclinical Studies
Bohari Bohari, Rimbawan Rimbawan, Zuraidah Nasution, Ekowati Handharyani
Preventive Nutrition and Food Science.2026;[Epub] CrossRef
Redefining β-Cell Function in Type 2 Diabetes Mellitus: From Comprehensive Assessment to Precision Medicine
YongKyung Kim, Joon Ha, Jun Sung Moon
Diabetes & Metabolism Journal.2026; 50(2): 235. CrossRef
β‐cell recovery revisited: Is prediabetes remission driven by insulin sensitivity or β‐cell function?
Joonyub Lee, Kun‐Ho Yoon
Journal of Diabetes Investigation.2026; 17(5): 716. CrossRef
Predicting 10-Year Diabetes Risk Through Physiological Acceleration: A Longitudinal Deep Learning Ensemble Approach
Sangsoo Kim, Seonghee Park, Jinmi Kim, Ha Jin Park, Soree Ryang, Myungsoo Im, Doohwa Kim, Kyeongjun Lee
Diagnostics.2026; 16(7): 992. CrossRef
Cost‐effectiveness analysis comparing real‐time continuous glucose monitoring with self‐monitoring of blood glucose for patients with type 2 diabetes treated with insulin in Japan
Hirotaka Watada, Shiro Tanaka, Jessica Y. Matuoka, Hamza Alshannaq, Richard F. Pollock, Martin Field, Gregory J. Norman
Journal of Diabetes Investigation.2026; 17(6): 989. CrossRef
High hepatic insulin resistance is linked to glucose and lipid profiles in Korean adults with type 2 diabetes
Paul Kim, Minji Kang, Hyunji Sang, Sang Youl Rhee, Hyunjung Lim
Frontiers in Endocrinology.2026;[Epub] CrossRef
Targeting PGC-1α by miRNA-374 Simultaneously Improve β-Cell Dysfunction and Suppress Hepatic Glucose Overproduction
Ji-Won Kim, Joonyub Lee, Young-Hye You, Chan-Hee Oh, Heon-Seok Park, Eun Young Lee, Seung-Hwan Lee, Seung-Hyun Ko, Ji-Ho Park, Kun-Ho Yoon
Diabetes & Metabolism Journal.2026; 50(3): 535. CrossRef
Revisiting GPR40 Agonist in Type 2 Diabetes Mellitus: A Cautious but Meaningful Return
Eun-Hee Cho
Diabetes & Metabolism Journal.2026; 50(3): 472. CrossRef
Association of Insulin Resistance with Dysglycemia in Elder Koreans: Age- and Sex-Specific Cutoff Values
Sang Min Yoon, Boyoung Park
Journal of Personalized Medicine.2025; 15(9): 438. CrossRef
Exploring Sex-Specific Mechanisms in Type 2 Diabetes Mellitus by Single-Cell Analysis in Pancreatic Islets
Joonyub Lee
Endocrinology and Metabolism.2025; 40(5): 699. CrossRef

Original Articles

Diabetes, obesity and metabolism
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis: A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta, Thanikai Sasikanth, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra; Endocrinol Metab. 2025;40(1):112-124. Published online January 15, 2025; DOI: https://doi.org/10.3803/EnM.2024.2164

76,510 View
794 Download
15 Web of Science
18 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
Methods
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases. The primary outcome was the overall risk of any cancer, and secondary outcomes were the risks of specific types of cancer in the tirzepatide versus the control groups.
Results
Thirteen RCTs with 13,761 participants were analyzed. Over 26 to 72 weeks, the tirzepatide and pooled control groups had identical risks of any cancer (risk ratio, 0.78; 95% confidence interval, 0.53 to 1.16; P=0.22). The two groups had comparable cancer risks in patients with and without diabetes. In subgroup analyses, the risks were also similar in the tirzepatide versus placebo, insulin, and glucagon-like peptide-1 receptor agonist groups. The overall cancer risk was also comparable for different doses of tirzepatide compared to the control groups; only a 10-mg tirzepatide dose had a lower risk of any cancer than placebo. Furthermore, compared to the control groups (pooled or separately), tirzepatide did not increase the risk of any specific cancer types. Despite greater increments in serum calcitonin with 10- and 15-mg tirzepatide doses than with placebo, the included RCTs reported no cases of papillary thyroid carcinoma.
Conclusion
Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk.

Citations

Citations to this article as recorded by

The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis
Karolina Hoffmann, Michał Michalak, Manfredi Rizzo, Viviana Maggio, Anna Paczkowska
Expert Opinion on Drug Safety.2026; 25(6): 1031. CrossRef
Tirzepatide and Obesity: A Narrative Review
Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
Advances in Human Biology.2026; 16(2): 290. CrossRef
Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management
Hamza A. Abdul‐Hafez, Ameer Awashra, Sosana Bdir, Sarah Saife, Qasem Salah, Mohammed Barbarawi, Thabet Swaileh, Ahmed Emara, Mohamed S. Elgendy, Abdalhakim Shubietah
Endocrinology, Diabetes & Metabolism.2026;[Epub] CrossRef
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown
Edoardo Mannucci, Ilaria Dicembrini
Nature Reviews Clinical Oncology.2026; 23(6): 459. CrossRef
Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Naseem Eisa, Omar Barood
AACE Endocrinology and Diabetes.2026; 13(3): 400. CrossRef
GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications
Sedat Arslan, Ayca Aydin
Academia Oncology.2026;[Epub] CrossRef
From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies
R. Modica, A. Liccardi, V. Zamponi, A. Gagliardi, A. Nistor, G. Veroi, A. Arecco, A. Faggiano, A. Colao
Endocrine.2026;[Epub] CrossRef
Short-term effect of tirzepatide on serum calcitonin in adults with obesity
Nikolaos Angelopoulos, George Simeakis, Ioannis Androulakis, Andreas Rizoulis, Anastasios Boniakos, Paraskevi Mentzelopoulou, Areti Korakovouni, Dimitra Zianni, Valentina Petkova, Sarantis Livadas, Rodis Paparodis
Endocrine.2026;[Epub] CrossRef
Dietary and pharmacological energy restriction and exercise for healthspan extension
Maria Lastra Cagigas, Isabella De Ciutiis, Andrius Masedunskas, Luigi Fontana
Trends in Endocrinology & Metabolism.2025; 36(6): 521. CrossRef
GLP-1 receptor agonists in the context of cancer: the road ahead
Isabelle R. Miousse
American Journal of Physiology-Cell Physiology.2025; 328(6): C1822. CrossRef
Treatment of type 2 diabetes mellitus - a current view of the different drug classes and strategies for their use
Jan Brož
Vnitřní lékařství.2025; 71(3): 144. CrossRef
Repurposing glucose-lowering drugs for cancer therapy
Michaela Luconi, Giulia Cantini, Clara Crescioli
Trends in Cancer.2025; 11(7): 691. CrossRef
Impact of 1-Year Tirzepatide Use on Glycemic and Metabolic Profile in Overweight to Obese People with Type 1 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Abul Bashar Mohammad Kamrul-Hasan, Ritin Mohindra, Nishant Raizada
Diabetes Technology and Obesity Medicine.2025;[Epub] CrossRef
Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions
Mariana Souto, Tiago Cúrdia Gonçalves, José Cotter
Nutrients.2025; 17(14): 2310. CrossRef
Weight loss interventions and obesity‐associated cancers in people with type 2 diabetes and overweight/obesity: A real‐world observational study
Testimony Ipaye, Jonathan Goldney, Thomas J. Wilkinson, Francesco Zaccardi, Thomas Yates, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis
Diabetes, Obesity and Metabolism.2025; 27(12): 6914. CrossRef
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A. Wellberg
Journal of Clinical Investigation.2025;[Epub] CrossRef
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Dario Tuccinardi, Davide Masi, Mikiko Watanabe, Valeria Zanghi Buffi, Francesco De Domenico, Sabrina Berti, Valentina Cipriani, Melania Manco, Silvia Manfrini, Uberto Pagotto
Journal of Endocrinological Investigation.2025; 48(12): 2761. CrossRef
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials
Ping-Tao Tseng, Bing-Yan Zeng, Chih-Wei Hsu, Cheuk-Kwan Sun, Mein-Woei Suen, Andre F. Carvalho, Brendon Stubbs, Yen-Wen Chen, Tien-Yu Chen, Wei-Te Lei, Po-Huang Chen, Jiann-Jy Chen, Yow-Ling Shiue, Bing-Syuan Zeng, Kuan-Pin Su, Chih-Sung Liang
Journal of Hematology & Oncology.2025;[Epub] CrossRef

Diabetes, obesity and metabolism
Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis: Jaehyun Bae, Min Heui Yu, Minyoung Lee, Bong-Soo Cha, Byung-Wan Lee; Endocrinol Metab. 2025;40(2):258-267. Published online January 13, 2025; DOI: https://doi.org/10.3803/EnM.2024.2120

6,938 View
215 Download
4 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Achieving optimal glucose control is essential in the management of type 2 diabetes (T2D). This study aimed to evaluate the effectiveness and safety of oral quadruple combination therapy for the treatment of T2D.
Methods
This meta-analysis reviewed original research on oral quadruple combination therapy for T2D, including both experimental and observational studies with a minimum duration of 12 weeks. The primary endpoint was the change in glycated hemoglobin (HbA1c) from baseline to follow-up. The secondary endpoint was the incidence rate of adverse events. Two investigators independently extracted data and assessed the risk of bias. Outcomes were pooled as the standardized mean difference (using Hedge’s g) and the risk ratio for adverse events in random-effects meta-analyses.
Results
The meta-analysis included 17 studies. Oral quadruple combination therapy resulted in an additional mean reduction in HbA1c levels of 1.1% in patients who did not achieve glycemic control with oral triple combination therapy. Compared with switching to injectables, such as insulin or a glucagon-like peptide-1 receptor agonist–containing regimen, this therapy was non-inferior, even demonstrating a slightly superior glucose-lowering effect. Furthermore, it was determined to be safe, with an adverse event rate of 0.25, indicating no significant difference in safety compared with adding a placebo or switching to an injectable-containing regimen.
Conclusion
Oral quadruple combination therapy is a valid option for patients with T2D who are unable to achieve glycemic targets with oral triple combination therapy, offering both effective glycemic control and a favorable safety profile.

Citations

Citations to this article as recorded by

Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24‐week, randomized, open‐label, multicenter trial
So Ra Kim, Jun Hwa Hong, Sin Gon Kim, Soo‐Kyung Kim, Hyuk‐Sang Kwon, Jun Sung Moon, Jung Hwan Park, Jae Myung Yu, Bong‐Soo Cha, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2026; 28(4): 3305. CrossRef
2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung-Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo-Kyung Kim, Young-eun Kim, Eun Sook Kim, Jae Hyeon Kim, Chong Hwa Kim, Ji Min Kim, Hae Jin Kim, Min Kyong Moon, Sun Joon Moon, Jun Sung
Diabetes & Metabolism Journal.2025; 49(4): 582. CrossRef
Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress
Ancuța Dinu (Iacob), Luminita-Georgeta Confederat, Ionut Dragostin, Ionela Daniela Morariu, Dana Tutunaru, Oana-Maria Dragostin
Current Issues in Molecular Biology.2025; 47(9): 709. CrossRef
2025 Clinical Practice Guidelines for Diabetes: Pharmacological Treatment of Type 2 Diabetes
Jong Han Choi
The Journal of Korean Diabetes.2025; 26(3): 158. CrossRef
Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
Jong Han Choi, Shinae Kang, Soo-Kyung Kim, Won Jun Kim, Ji Min Kim, Jaehyun Bae, Jae-Seung Yun, Eonju Jeon, Young-Eun Kim, Jae Hyun Bae, Hun Jee Choe, Young Min Cho, Seung-Hyun Ko, Sang Yong Kim, Hae Jin Kim, You-Cheol Hwang, Min Kyong Moon, Suk Chon, Seo
Diabetes & Metabolism Journal.2025; 49(6): 1155. CrossRef

Brief Report

Diabetes, obesity and metabolism
Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes: Hun Jee Choe, Michael A. Nauck, Joon Ho Moon; Endocrinol Metab. 2025;40(1):156-160. Published online November 25, 2024; DOI: https://doi.org/10.3803/EnM.2024.2150

5,583 View
116 Download
5 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader ePub

In the context of a global shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, we assessed the impact of discontinuing dulaglutide on metabolic control in individuals with type 2 diabetes. Our analysis included data from 69 individuals and revealed a significant deterioration in glycemic control following the discontinuation. Specifically, the average hemoglobin A1c level increased from 7.0%±0.9% to 8.1%±1.4% (P<0.001), and fasting glucose levels rose from 129±31 to 156±50 mg/dL (P<0.001) within 3 months after stopping the medication. Alternative treatments such as dipeptidyl peptidase-4 inhibitors and sodium glucose cotransporter- 2 inhibitors were insufficient substitutes, highlighting the essential role of continuous GLP-1 receptor agonist therapy in maintaining metabolic health.

Citations

Citations to this article as recorded by

Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study
Christian Dacon, Pramodini Kale-Pradhan, Melissa Lipari
Journal of Pharmacy Practice.2026;[Epub] CrossRef
Metabolic rebound and weight cycling following incretin mimetic drug withdrawal: a cause for concern?
Sarah E. Alexander, Erin J. Howden
Current Opinion in Clinical Nutrition & Metabolic Care.2026; 29(4): 395. CrossRef
Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
Velimir Altabas, Zrinka Orlović, Maja Baretić
Diabetology.2025; 6(6): 52. CrossRef
Use of gastric ultrasound to identify GLP-1RA users at high risk of aspiration during surgery
Alessandra T. Ayers, Cindy N. Ho, Nicole Y. Xu, Sergio D. Bergese, Ana Costa, David Kerr, David C. Klonoff
Perioperative Care and Operating Room Management.2025; 41: 100562. CrossRef
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions
Afsaneh Shirani, Olaf Stuve
Expert Opinion on Investigational Drugs.2025; 34(11): 929. CrossRef
Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kornela Kotucha, Katarzyna Kapłon, Magdalena Moś, Jakub Fiegler-Rudol, Alina Pietryszyn-Bilińska, Klaudia Dynarowicz, David Aebisher, Rafał Wiench, Aleksandra Kawczyk-Krupka
European Journal of Clinical and Experimental Medicine.2025;[Epub] CrossRef

Original Articles

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Risk of Diabetes Mellitus in Adults with Intellectual Disabilities: A Nationwide Cohort Study: Hye Yeon Koo, In Young Cho, Yoo Jin Um, Yong-Moon Mark Park, Kyung Mee Kim, Chung Eun Lee, Kyungdo Han; Endocrinol Metab. 2025;40(1):103-111. Published online November 20, 2024; DOI: https://doi.org/10.3803/EnM.2024.2126

4,299 View
123 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Intellectual disability (ID) may be associated with an increased risk of diabetes mellitus (DM). However, evidence from longitudinal studies is scarce, particularly in Asian populations.
Methods
This retrospective cohort study used representative linked data from the Korea National Disability Registration System and the National Health Insurance Service database. Adults (≥20 years) who received a national health examination in 2009 (3,385 individuals with ID and 3,463,604 individuals without ID) were included and followed until 2020. ID was identified using legal registration information. Incident DM was defined by prescription records with relevant diagnostic codes. Multivariable-adjusted Cox proportional hazards regression models were used to estimate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) for DM risks in individuals with ID compared to those without ID.
Results
Over a mean follow-up of 9.8 years, incident DM occurred in 302 (8.9%) individuals with ID and 299,156 (8.4%) individuals without ID. Having ID was associated with increased DM risk (aHR, 1.38; 95% CI, 1.23 to 1.55). Sensitivity analysis confirmed a higher DM risk in individuals with ID (aHR, 1.39; 95% CI, 1.24 to 1.56) than those with other disabilities (aHR, 1.11; 95% CI, 1.10 to 1.13) or no disability (reference). Stratified analysis showed higher DM risk in non-hypertensive subjects (aHR, 1.63; 95% CI, 1.43 to 1.86) compared to hypertensive subjects (aHR, 1.00; 95% CI, 0.80 to 1.26; P for interaction <0.001).
Conclusion
Adults with ID have an increased risk of developing DM, highlighting the need for targeted public health strategies to promote DM prevention in this population.

Diabetes, obesity and metabolism
Importance of the Hemoglobin Glycation Index for Risk of Cardiovascular and Microvascular Complications and Mortality in Individuals with Type 2 Diabetes: Claudia Regina Lopes Cardoso, Nathalie Carvalho Leite, Gil Fernando Salles; Endocrinol Metab. 2024;39(5):732-747. Published online October 15, 2024; DOI: https://doi.org/10.3803/EnM.2024.2001

5,405 View
97 Download
14 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the prognostic importance of the hemoglobin glycation index (HGI) for macrovascular and microvascular outcomes, mortality, and hypoglycemia occurrence in a type 2 diabetes cohort and compared it to glycated hemoglobin (HbA1c).
Methods
Baseline and mean first-year HGI and HbA1c, and the variability thereof, were assessed in 687 individuals with type 2 diabetes (median follow-up, 10.6 years). Multivariable Cox regression was conducted to evaluate the associations of HGI and HbA1c parameters with macrovascular (total and major cardiovascular events) and microvascular outcomes (microalbuminuria, advanced renal failure, retinopathy, and peripheral neuropathy), mortality (all-cause and cardiovascular), and moderate/severe hypoglycemia occurrence.
Results
During follow-up, there were 215 total cardiovascular events (176 major) and 269 all-cause deaths (131 cardiovascular). Microalbuminuria developed in 126 patients, renal failure in 104, retinopathy in 161, and neuropathy in 177. There were 90 hypoglycemia episodes. Both HGI and HbA1c predicted all adverse outcomes, except microalbuminuria and hypoglycemia. Their adjusted risks were roughly equivalent for all outcomes. For example, the adjusted hazard ratios (HRs) with 95% confidence intervals (CIs), estimated for 1 standard deviation increments, of mean first-year HGI were 1.23 (1.05 to 1.44), 1.20 (1.03 to 1.38), 1.36 (1.11 to 1.67), 1.28 (1.09 to 1.67), and 1.29 (1.09 to 1.54), respectively, for cardiovascular events, all-cause mortality, renal failure, retinopathy, and neuropathy; whereas the respective HRs (95% CIs) of mean HbA1c were 1.31 (1.12 to 1.53), 1.28 (1.11 to 1.48), 1.36 (1.11 to 1.67), 1.33 (1.14 to 1.55), and 1.29 (1.09 to 1.53).
Conclusion
HGI was no better than HbA1c as a predictor of adverse outcomes in individuals with type 2 diabetes, and its clinical use cannot be currently advised.

Citations

Citations to this article as recorded by

Association of hemoglobin glycation index and diabetic retinopathy results from NHANES
Ning Feng, Guang-Jie Cheng, Shun-Feng Zhao, Lin-Jun Du, Ning Guo, Na Zhang
International Journal of Diabetes in Developing Countries.2026; 46(1): 185. CrossRef
Association between glycated hemoglobin variability and risk of diabetic kidney disease and diabetic retinopathy in diabetic patients: a systematic review and meta-analysis
Chan Wu, Hanrong Qin, Maoying Wei, Aijing Li, Qingyi Zhu, Jingyi Guo, Anning Sun, Xin Gu, Yincheng Li, Jun Zhang, Yanbing Gong
Frontiers in Endocrinology.2026;[Epub] CrossRef
Development and validation of a clinical prediction model for overactive bladder in type 2 diabetes: a pathophysiology-informed approach
Meiyuan Lv, Guangxu Fu, Dongfeng Yi, Zhihua Zhang, Liangbing Liu
European Journal of Medical Research.2026;[Epub] CrossRef
Hemoglobin glycation index and renal progression in patients with type 2 diabetes: a 5-year cohort study
Chin-Sung Kuo, Nai-Rong Kuo, Fu-Shun Ko, Po-Hsun Huang, Chii-Min Hwu
Endocrine.2026;[Epub] CrossRef
L-shaped relationship between hemoglobin glycation index and short-term mortality in patients with intracerebral hemorrhage: A retrospective cohort study
Jia Xu, Guangdong Wang, Yongfeng Ni, Zhiyuan Ren
PLOS One.2026; 21(5): e0348436. CrossRef
Hemoglobin glycation index and rapid kidney function decline in diabetes patients: Insights from CHARLS
Fan Zhang, Rui Zhou, Yan Bai, Liuyan Huang, Jiao Li, Yifei Zhong
Diabetes Research and Clinical Practice.2025; 222: 112054. CrossRef
Association Between the Hemoglobin Glycation Index (HGI) and Risk of Diabetic Nephropathy: A Retrospective Cohort Study
Weiyi Zhou, Lingyu Zhang, Tongqiang Liu
Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 1859. CrossRef
Association between hemoglobin glycation index and 28-day all-cause mortality in acute myocardial infarction patients: Analysis of the MIMIC-IV database
Yue Lv, Lingchen Wei, Ziyue Wang, Zichuan Mu, Jianlin Wu, Fuad Abdu,
PLOS One.2025; 20(9): e0330819. CrossRef
Distinct patterns of association between the hemoglobin glycation index, the stress–hyperglycemia ratio, and the risk of new-onset atrial fibrillation in critically ill patients
Qiqiang Jie, Gang Li, Weichun Qian, Mingzhu He, Haibo Jia, Fengfu Zhang, Jianping Wang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Glycemic variability of glycated hemoglobin in patients with type 2 diabetes mellitus and the risk of cardiovascular diseases: a latest systematic review and meta-analysis
Chan Wu, Aijing Li, Qingyi Zhu, Jingyi Guo, Yincheng Li, Xin Gu, Anning Sun, Maoying Wei, Yanbing Gong
Frontiers in Endocrinology.2025;[Epub] CrossRef
Hemoglobin glycation index predicts reduced mortality in critically ill patients with chronic kidney disease
Yangpei Peng, Wenwen Huang, Jie Wang
Clinics.2025; 80: 100812. CrossRef

Review Article

Diabetes, obesity and metabolism
Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures: Kyoung Hwa Ha, Dae Jung Kim; Endocrinol Metab. 2024;39(5):669-677. Published online September 25, 2024; DOI: https://doi.org/10.3803/EnM.2024.2073

17,941 View
302 Download
13 Web of Science
15 Crossref

Abstract PDF Supplementary Material PubReader ePub

Diabetes is a serious public health concern that significantly contributes to the global burden of disease. In Korea, the prevalence of diabetes is 12.5% among individuals aged 19 and older, and 14.8% among individuals aged 30 and older as of 2022. The total number of people with diabetes among those aged 19 and older is estimated to be 5.4 million. The incidence of diabetes decreased from 8.1 per 1,000 persons in 2006 to 6.3 per 1,000 persons in 2014, before rising again to 7.5 per 1,000 persons in 2019. Meanwhile, the incidence of type 1 diabetes increased significantly, from 1.1 per 100,000 persons in 1995 to 4.8 per 100,000 persons in 2016, with the prevalence reaching 41.0 per 100,000 persons in 2017. Additionally, the prevalence of gestational diabetes saw a substantial rise from 4.1% in 2007 to 22.3% in 2023. These changes have resulted in increases in the total medical costs for diabetes, covering both outpatient and inpatient services. Therefore, effective diabetes prevention strategies are urgently needed.

Citations

Citations to this article as recorded by

Age-stratified comorbidity transitions and interconnected mapping of nine allergic diseases
Ju Hee Kim, Eun Lee, Jeewon Shin, Eunkyo Ha, Hana Yoo, Soonchul Lee, Man Yong Han
Allergology International.2026; 75(2): 252. CrossRef
Postpartum Glucose Intolerance in Women with a History of Gestational Diabetes Mellitus: An In-Depth Review
Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho
Endocrinology and Metabolism.2026; 41(1): 26. CrossRef
Diabetes in Pregnancy in Korea: Prevalence, Clinical Characteristics, and Postpartum Comorbidities
Joon Ho Moon, Han Na Jung, Bongseong Kim, Seung-Hyun Ko, Soo Heon Kwak, Kyung-Do Han, Sung Hee Choi
Diabetes & Metabolism Journal.2026; 50(2): 280. CrossRef
Prevalence, Diagnostic Role, and Clinical Features of Zinc Transporter 8 Autoantibody in Korean Children and Adolescents With Diabetes Mellitus
Sohyun Shin, Hyun Ah Woo, Hakyung Lee, Yun Jeong Lee, Hwa Young Kim, Young Ah Lee, Choong Ho Shin, Ho Young Lee, Jaehyun Kim
Journal of Korean Medical Science.2026;[Epub] CrossRef
Trends in Low Muscle Mass and Sarcopenia Prevalence in Korea Using Korea National Health and Nutrition Examination Survey (KNHANES) 2024 and 2008–2011: The KSBMR-KSOS KNHANES DXA Joint Task Force Report
Namki Hong, Jun-Il Yoo, Jeonghoon Ha, Seong Hee Ahn, Young-Kyun Lee, Hyun Sik Gong, Ki-Hyun Baek, Yumie Rhee, Yong-Chan Ha
Journal of Bone Metabolism.2026; 33(2): 197. CrossRef
Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
Journal of Diabetes Investigation.2025; 16(2): 215. CrossRef
Effects of Black Cumin Seed Extract on Pancreatic Islet β-Cell Proliferation and Hypoglycemic Activity in Streptozotocin-Induced Diabetic Rats
Jongkyu Kim, Yoon-Seok Chun, Namkyu Yoon, Byungkwon Kim, Kiin Choi, Sae-Kwang Ku, Namju Lee
Antioxidants.2025; 14(2): 174. CrossRef
Older Adults with Diabetes in Korea: Latest Clinical and Epidemiologic Trends
Kyuho Kim, Bongseong Kim, Kyuna Lee, Yu-Bae Ahn, Seung-Hyun Ko, Sung Hee Choi, Kyungdo Han, Jae-Seung Yun
Diabetes & Metabolism Journal.2025; 49(2): 183. CrossRef
Elevated triglyceride-glucose index is a risk factor for cardiovascular events in adults with type 1 diabetes: a cohort study
Rosa Oh, Seohyun Kim, Sang Ho Park, Myunghwa Jang, So Hyun Cho, Ji Yoon Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim
Cardiovascular Diabetology.2025;[Epub] CrossRef
Association Between Healthy Dietary Patterns and Chronic Kidney Disease in Patients with Diabetes: Findings from Korean National Health and Nutrition Examination Survey 2019–2021
Minsang Kim, Jung Koh, Jeong Cho, Semin Cho, Soojin Lee, Hyuk Huh, Seong Kim, Sehyun Jung, Eunjeong Kang, Sehoon Park, Jin Paek, Woo Park, Kyubok Jin, Seungyeup Han, Kwon Joo, Kyungdo Han, Dong Kim, Yaerim Kim
Nutrients.2025; 17(9): 1600. CrossRef
Start Early, Do It Well: Implications of a National Diabetes Care Quality Assessment Program for Life Expectancy
Kyoung Hwa Ha, Dae Jung Kim
Diabetes & Metabolism Journal.2025; 49(5): 987. CrossRef
Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
Jong Han Choi, Shinae Kang, Soo-Kyung Kim, Won Jun Kim, Ji Min Kim, Jaehyun Bae, Jae-Seung Yun, Eonju Jeon, Young-Eun Kim, Jae Hyun Bae, Hun Jee Choe, Young Min Cho, Seung-Hyun Ko, Sang Yong Kim, Hae Jin Kim, You-Cheol Hwang, Min Kyong Moon, Suk Chon, Seo
Diabetes & Metabolism Journal.2025; 49(6): 1155. CrossRef
Pharmacoacupuncture for Lowering HbA1c in Korean Adult Patients With Hyperglycemia: A Retrospective Study
Ju-young Lee, Youngeun Yoo, Sanghun Lee
Acupuncture & Electro-Therapeutics Research: International Journal of Integrated Medicine.2025; 49(4): 230. CrossRef
Association of diabetes, obesity, and their co-occurrence with suicide ideation in Korean adults using nationally representative data from 2019 to 2021
Shiva Raj Acharya, Sudarshan Subedi, Diwash Timilsina
Scientific Reports.2025;[Epub] CrossRef
Real-World Utility of GWAS-Based Diabetes Mellitus Panel Testing
In Hwa Jeong, Kyung-Won Hong, Ja-Eun Choi, Bo-Kyung Shine
International Journal of Molecular Sciences.2025; 27(1): 275. CrossRef

Original Article

Diabetes, obesity and metabolism
Impact of Chronic Kidney Disease and Gout on End-Stage Renal Disease in Type 2 Diabetes: Population-Based Cohort Study: Inha Jung, Da Young Lee, Seung Min Chung, So Young Park, Ji Hee Yu, Jun Sung Moon, Ji A Seo, Kyungdo Han, Nan Hee Kim; Endocrinol Metab. 2024;39(5):748-757. Published online August 30, 2024; DOI: https://doi.org/10.3803/EnM.2024.2020

7,104 View
103 Download
6 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We examined the impact of gout on the end-stage renal disease (ESRD) risk in patients with type 2 diabetes mellitus (T2DM) and determined whether this association differs according to chronic kidney disease (CKD) status.
Methods
Using the Korean National Health Insurance Service, this nationwide cohort study enrolled 847,884 patients with T2DM who underwent health checkups in 2009. Based on the presence of CKD (estimated glomerular filtration rate <60 mL/min/1.73 m²) and gout (two outpatient visits or one hospitalization within 5 years), patients were classified into four groups: CKD⁻Gout⁻, CKD⁻ Gout⁺, CKD⁺Gout⁻, and CKD⁺Gout⁺. Patients with incident ESRD were followed up until December 2018.
Results
Among 847,884 patients, 11,825 (1.4%) experienced progression to ESRD. ESRD incidence increased in the following order: 0.77 per 1,000 person-years (PY) in the CKD⁻Gout⁻ group, 1.34/1,000 PY in the CKD⁻Gout⁺ group, 8.20/1,000 PY in the CKD⁺Gout⁻ group, and 23.06/1,000 PY in the CKD⁺Gout⁺ group. The presence of gout modified the ESRD risk in a status-dependent manner. Hazard ratios (HR) were 1.49 (95% confidence interval [CI], 1.32 to 1.69) and 2.24 (95% CI, 2.09 to 2.40) in patients without and with CKD, respectively, indicating a significant interaction (P<0.0001). The CKD⁺Gout⁺ group had a markedly higher risk of developing ESRD (HR, 18.9; 95% CI, 17.58 to 20.32) than the reference group (CKD⁻Gout⁻).
Conclusion
Gout substantially enhances the risk of ESRD, even in the absence of CKD. Concurrent CKD and gout synergistically increase the risk of ESRD. Therefore, physicians should carefully screen for hyperuricemia to prevent progression to ESRD.

Citations

Citations to this article as recorded by

Undescribed phenylspirodrimane dimers with anti-gouty activity from the coral-derived fungus Stachybotrys chartarum
Shuang Lin, Yi-Fan Geng, Hanxiao Zeng, Zixue Chai, Baolei Fan, Jun-Cheng Su, Yonghui Zhang, Zhengxi Hu
Phytochemistry.2026; 248: 114891. CrossRef
Gout in the era of multimorbidity: pathogenesis, systemic comorbidities, and evolving therapeutic strategies
Phillip J Kim, Jihun Kang, Jesang Yu, Geun-Tae Kim, Yunkyung Kim
Kosin Medical Journal.2026; 41(1): 26. CrossRef
Acute gout attack in a peritoneal dialysis patient treated with Firsekibart: a case report
Wenqian Wei, Lijie Gu, Hanyu Meng, Nan Zhu, Shu Rong
Open Medicine.2026;[Epub] CrossRef
Polydatin alleviates adenine-induced nephropathy in mice
Tao Sheng, Tianhong Ma, Xin Jin, Debin Chen, Shipeng Che, Jie Wang, Jiadu Shen, Chaoqun Shi, Qiang Li, Yixin Sun, Deqing Chen, Guangtao Xu
Renal Failure.2026;[Epub] CrossRef
Heterogeneity in the development of diabetes-related complications: narrative review of the roles of ancestry and geographical determinants
Andrea O. Y. Luk, Yingnan Fan, Baoqi Fan, Edith W. K. Chow, Tony C. K. O
Diabetologia.2025; 68(11): 2386. CrossRef
Relationship between the Chinese visceral adiposity index and gout in individuals with type 2 diabetes mellitus: a cross-sectional population-based study
Ningyu Cai, Mengdie Chen, Ping Feng, Yiyun Wang, Xianping Zhu, Qidong Zheng
Frontiers in Nutrition.2025;[Epub] CrossRef

Brief Report

Diabetes, obesity and metabolism
Impact of Diabetes on COVID-19 Susceptibility: A Nationwide Propensity Score Matching Study: Han Na Jang, Sun Joon Moon, Jin Hyung Jung, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee; Endocrinol Metab. 2024;39(5):813-818. Published online August 28, 2024; DOI: https://doi.org/10.3803/EnM.2024.2014

3,615 View
52 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Prior research has highlighted poor clinical outcomes in coronavirus disease 2019 (COVID-19)-infected patients with diabetes; however, susceptibility to COVID-19 infection in patients with diabetes has not been extensively studied. Participants aged ≥30 years who underwent COVID-19 testing from December 2019 to April 2020 were analyzed using the National Health Insurance Service data in South Korea. In a cohort comprising 29,433 1:1 propensity score-matched participants, COVID-19 positivity was significantly higher in participants with diabetes than in those without diabetes (512 [3.5%] vs. 395 [2.7%], P<0.001). Logistic regression analysis indicated that diabetes significantly increased the risk of COVID-19 test positivity (odds ratio, 1.307; 95% confidence interval, 1.144 to 1.493; P<0.001). Patients with diabetes exhibited heightened COVID-19 infection rates compared to individuals without diabetes, and diabetes increased the susceptibility to COVID-19, reinforcing the need for heightened preventive measures, particularly considering the poor clinical outcomes in this group.

Citations

Citations to this article as recorded by

The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes
Hongjuan Fang, Qiang Wang
Journal of Translational Medicine.2026;[Epub] CrossRef
Underweight Status Amplifies Respiratory Infection Mortality in Diabetes: Findings From a Nationwide Cohort Study
Hun Jee Choe, Kyong Do Han, Ji‐Hong Park, Jiwoo Lee, Mi Kyung Kwak, Yun Mi Choi, Sun‐Joon Moon, Eun‐Gyoung Hong
Journal of Cachexia, Sarcopenia and Muscle.2026;[Epub] CrossRef

Original Articles

Diabetes, obesity and metabolism
Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE): Nam Hoon Kim, Juneyoung Lee, Suk Chon, Jae Myung Yu, In-Kyung Jeong, Soo Lim, Won Jun Kim, Keeho Song, Ho Chan Cho, Hea Min Yu, Kyoung-Ah Kim, Sang Soo Kim, Soon Hee Lee, Chong Hwa Kim, Soo Heon Kwak, Yong‐ho Lee, Choon Hee Chung, Sihoon Lee, Heung Yong Jin, Jae Hyuk Lee, Gwanpyo Koh, Sang-Yong Kim, Jaetaek Kim, Ju Hee Lee, Tae Nyun Kim, Hyun Jeong Jeon, Ji Hyun Lee, Jae-Han Jeon, Hye Jin Yoo, Hee Kyung Kim, Hyeong-Kyu Park, Il Seong Nam-Goong, Seongbin Hong, Chul Woo Ahn, Ji Hee Yu, Jong Heon Park, Keun-Gyu Park, Chan Ho Park, Kyong Hye Joung, Ohk-Hyun Ryu, Keun Yong Park, Eun-Gyoung Hong, Bong-Soo Cha, Kyu Chang Won, Yoon-Sok Chung, Sin Gon Kim; Endocrinol Metab. 2024;39(5):722-731. Published online August 22, 2024; DOI: https://doi.org/10.3803/EnM.2024.1995

12,239 View
350 Download
7 Web of Science
5 Crossref

Abstract PDF PubReader ePub

Background
Atherogenic dyslipidemia, which is frequently associated with type 2 diabetes (T2D) and insulin resistance, contributes to the development of vascular complications. Statin therapy is the primary approach to dyslipidemia management in T2D, however, the role of non-statin therapy remains unclear. Ezetimibe reduces cholesterol burden by inhibiting intestinal cholesterol absorption. Fibrates lower triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C) levels via peroxisome proliferator- activated receptor alpha agonism. Therefore, when combined, these drugs effectively lower non-HDL-C levels. Despite this, few clinical trials have specifically targeted non-HDL-C, and the efficacy of triple combination therapies, including statins, ezetimibe, and fibrates, has yet to be determined.
Methods
This is a multicenter, prospective, randomized, open-label, active-comparator controlled trial involving 3,958 eligible participants with T2D, cardiovascular risk factors, and elevated non-HDL-C (≥100 mg/dL). Participants, already on moderate-intensity statins, will be randomly assigned to either Ezefeno (ezetimibe/fenofibrate) addition or statin dose-escalation. The primary end point is the development of a composite of major adverse cardiovascular and diabetic microvascular events over 48 months.
Conclusion
This trial aims to assess whether combining statins, ezetimibe, and fenofibrate is as effective as, or possibly superior to, statin monotherapy intensification in lowering cardiovascular and microvascular disease risk for patients with T2D. This could propose a novel therapeutic approach for managing dyslipidemia in T2D.

Citations

Citations to this article as recorded by

Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy
Mengying Liu, Seok Ting Lim, Weihua Song, Thomas M. Coffman, Xiaomeng Wang
Trends in Pharmacological Sciences.2026; 47(3): 325. CrossRef
Differential Pre‐ and Post‐Treatment Effects of Low‐Dose Antidyslipidemic Drugs on Gentamicin‐Induced Acute Nephrotoxicity in the Rat: A Histopathological and Biochemical Study
Pitchai Balakumar, Sultan Alshahrani, Noohu Abdulla Khan, Rajavel Varatharajan, K. M. Sundram
Journal of Applied Toxicology.2026; 46(6): 1879. CrossRef
Ezetimibe attenuates diabetic retinopathy via NRF2-mediated suppression of inflammation and oxidative stress
Lei Cheng, Shan Cheng, Ran Zhu, Guoxu Xu
Journal of Diabetes and its Complications.2026; 40(2): 109250. CrossRef
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Jakub Michal Zimodro, Manfredi Rizzo, Ioanna Gouni-Berthold
Pharmaceuticals.2025; 18(2): 147. CrossRef
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study
Ji Yoon Kim, Nam Hoon Kim, Jiyoon Lee, Dong-Hoon Kim, Sin Gon Kim
European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(7): 620. CrossRef

Diabetes, obesity and metabolism
Amelioration of Insulin Resistance after Delivery Is Associated with Reduced Risk of Postpartum Diabetes in Women with Gestational Diabetes Mellitus: Heejun Son, Joon Ho Moon, Sung Hee Choi, Nam H. Cho, Soo Heon Kwak, Hak Chul Jang; Endocrinol Metab. 2024;39(5):701-710. Published online August 21, 2024; DOI: https://doi.org/10.3803/EnM.2024.1974

6,341 View
90 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Identifying risk factors for postpartum type 2 diabetes in women with gestational diabetes mellitus (GDM) is crucial for effective interventions. We examined whether changes in insulin sensitivity after delivery affects the risk of type 2 diabetes in women with GDM.
Methods
This prospective cohort study included 347 women with GDM or gestational impaired glucose tolerance, who attended the follow-up visits at 2 months postpartum and annually thereafter. Changes in insulin sensitivity were calculated using the Matsuda index at GDM diagnosis and at 2 months postpartum (ΔMatsuda index). After excluding women with pregestational diabetes or those followed up only once, we analyzed the risk of postpartum type 2 diabetes based on the ΔMatsuda index tertiles.
Results
The incidence of type 2 diabetes at the two-month postpartum visit decreased with increasing ΔMatsuda index tertiles (16.4%, 9.5%, and 1.8%, P=0.001). During a 4.1-year follow-up, 26 out of 230 women who attended more than two follow-up visits (11.3%) developed type 2 diabetes. Compared to the lowest tertile, subjects in the highest ΔMatsuda index tertile showed a significantly reduced risk of type 2 diabetes (hazard ratio, 0.33; 95% confidence interval, 0.12 to 0.93; P=0.036) after adjusting for confounders.
Conclusion
Improvement in insulin sensitivity after delivery is associated with a reduced risk of postpartum type 2 diabetes in women with GDM. Postpartum changes in insulin sensitivity could be a useful prediction for future type 2 diabetes development in women with GDM.

Citations

Citations to this article as recorded by

Postpartum Glucose Intolerance in Women with a History of Gestational Diabetes Mellitus: An In-Depth Review
Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho
Endocrinology and Metabolism.2026; 41(1): 26. CrossRef
Gestational Diabetes Mellitus: Mechanisms Underlying Maternal and Fetal Complications
Jooyeop Lee, Na Keum Lee, Joon Ho Moon
Endocrinology and Metabolism.2025; 40(1): 10. CrossRef
Evaluation of Maternal Factors Affecting Postpartum Insulin Resistance Markers in Mothers with Gestational Diabetes—A Case–Control Study
Karolina Karcz, Paulina Gaweł, Barbara Królak-Olejnik
Nutrients.2024; 16(22): 3871. CrossRef

Diabetes, obesity and metabolism
Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease: Hun Jee Choe, Yeh-Hee Ko, Sun Joon Moon, Chang Ho Ahn, Kyoung Hwa Ha, Hyeongsuk Lee, Jae Hyun Bae, Hyung Joon Joo, Hyejin Lee, Jang Wook Son, Dae Jung Kim, Sin Gon Kim, Kwangsoo Kim, Young Min Cho; Endocrinol Metab. 2024;39(4):622-631. Published online August 1, 2024; DOI: https://doi.org/10.3803/EnM.2024.1965

7,702 View
94 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Dipeptidyl peptidase-4 (DPP4) inhibitors are frequently prescribed for patients with type 2 diabetes; however, their cost can pose a significant barrier for those with impaired kidney function. This study aimed to estimate the economic benefits of substituting non-renal dose-adjusted (NRDA) DPP4 inhibitors with renal dose-adjusted (RDA) DPP4 inhibitors in patients with both impaired kidney function and type 2 diabetes.
Methods
This retrospective cohort study was conducted from January 1, 2012 to December 31, 2018, using data obtained from common data models of five medical centers in Korea. Model 1 applied the prescription pattern of participants with preserved kidney function to those with impaired kidney function. In contrast, model 2 replaced all NRDA DPP4 inhibitors with RDA DPP4 inhibitors, adjusting the doses of RDA DPP4 inhibitors based on individual kidney function. The primary outcome was the cost difference between the two models.
Results
In total, 67,964,996 prescription records were analyzed. NRDA DPP4 inhibitors were more frequently prescribed to patients with impaired kidney function than in those with preserved kidney function (25.7%, 51.3%, 64.3%, and 71.6% in patients with estimated glomerular filtration rates [eGFRs] of ≥60, <60, <45, and <30 mL/min/1.73 m², respectively). When model 1 was applied, the cost savings per year were 7.6% for eGFR <60 mL/min/1.73 m² and 30.4% for eGFR <30 mL/min/1.73 m². According to model 2, 15.4% to 51.2% per year could be saved depending on kidney impairment severity.
Conclusion
Adjusting the doses of RDA DPP4 inhibitors based on individual kidney function could alleviate the economic burden associated with medical expenses.

Citations

Citations to this article as recorded by

Nephroprotective Potential of Linagliptin and Glimepiride: a Comprehensive Review
Sumaira Tasleem, Farogh Ahsan, Shahzadi Bano, Tarique Mahmood, Asad Ahmad, Soheir A. A. Hagras, Mohammad Sarafroz, Syed Mehdi Hasan Zaidi, Divyanshi Saxena
Current Pharmacology Reports.2026;[Epub] CrossRef

Brief Report

Diabetes, obesity and metabolism
Ketonuria as an Indicator of Improvement of Renal Function in Patients with Type 2 Diabetes Receiving SGLT2 Inhibitor Treatment: Hyun Ah Kim, Han Na Jang, Sung Hye Kong, Young Lee, Sung Hee Choi, Young Min Cho, Hak Chul Jang, Tae Jung Oh; Endocrinol Metab. 2024;39(4):653-658. Published online May 16, 2024; DOI: https://doi.org/10.3803/EnM.2024.1919

6,752 View
164 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

We investigated the potential association between ketonuria during treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors and its renoprotective effect in patients with type 2 diabetes. We included 192 patients who had received SGLT2 inhibitors for more than 6 months. After propensity score matching, 52 patients each were allocated into groups with or without ketonuria, respectively. The estimated glomerular filtration rate exhibited a significant improvement only in subjects with ketonuria (without ketonuria: mean difference, –0.02 mL/min/1.73 m² [95% confidence interval (CI), –3.87 to 3.83 mL/min/1.73 m²] vs. with ketonuria: mean difference, 6.81 mL/min/1.73 m² [95% CI, 3.16 to 10.46 mL/min/1.73 m²]; P<0.001). Improvement in estimated glomerular filtration rate at 6 months was associated with female sex and lower baseline body weight, blood pressure, and triglyceride levels in patients with ketonuria. In conclusion, the presence of ketonuria was associated with the renoprotective effect of SGLT2 inhibitors, and female sex and the absence of metabolic syndrome components may serve as additional indicators of these medications’ substantial renoprotective effects in individuals with ketonuria.

Citations

Citations to this article as recorded by

Effects of a continuous remote care intervention including nutritional ketosis on kidney function and inflammation in adults with type 2 diabetes: a post-hoc latent class trajectory analysis
Shaminie J. Athinarayanan, Caroline G. P. Roberts, Stephen D. Phinney, Thomas Weimbs, Allon N. Friedman, Jeff S. Volek
Frontiers in Nutrition.2025;[Epub] CrossRef
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh
Endocrinology and Metabolism.2025; 40(6): 851. CrossRef
Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression
Melina Messing, Jacob A. Torres, Nickolas Holznecht, Thomas Weimbs
Nutrients.2024; 16(19): 3281. CrossRef

Review Articles

Diabetes, obesity and metabolism
Scaling Insulin-Producing Cells by Multiple Strategies: Jinhyuk Choi, Fritz Cayabyab, Harvey Perez, Eiji Yoshihara; Endocrinol Metab. 2024;39(2):191-205. Published online April 4, 2024; DOI: https://doi.org/10.3803/EnM.2023.1910

9,122 View
213 Download
4 Web of Science
4 Crossref

Abstract PDF PubReader ePub

In the quest to combat insulin-dependent diabetes mellitus (IDDM), allogenic pancreatic islet cell therapy sourced from deceased donors represents a significant therapeutic advance. However, the applicability of this approach is hampered by donor scarcity and the demand for sustained immunosuppression. Human induced pluripotent stem cells are a game-changing resource for generating synthetic functional insulin-producing β cells. In addition, novel methodologies allow the direct expansion of pancreatic progenitors and mature β cells, thereby circumventing prolonged differentiation. Nevertheless, achieving practical reproducibility and scalability presents a substantial challenge for this technology. As these innovative approaches become more prominent, it is crucial to thoroughly evaluate existing expansion techniques with an emphasis on their optimization and scalability. This manuscript delineates these cutting-edge advancements, offers a critical analysis of the prevailing strategies, and underscores pivotal challenges, including cost-efficiency and logistical issues. Our insights provide a roadmap, elucidating both the promises and the imperatives in harnessing the potential of these cellular therapies for IDDM.

Citations

Citations to this article as recorded by

Reconstructing the Islets: Advances in 3D Pancreatic Organoid Models for Functional β-Cell Replacement
Muhammad Kamal Hossain, Hyung-Ryong Kim
International Journal of Molecular Sciences.2026; 27(3): 1280. CrossRef
Advances in stem cell–derived beta-cell therapy: A new frontier in type 1 diabetes treatment
Krishnaa Shivkant Upadhye, Paritosh Tayade
Cell Transplantation.2026;[Epub] CrossRef
The Last Mile in Beta-Cell Replacement Therapy for Type 1 Diabetes: Time to Grow Up
Lorenzo Piemonti
Transplant International.2025;[Epub] CrossRef
Insulin evolution: A holistic view of recombinant production advancements
Ansuman Sahoo, Prabir Kumar Das, Veeranki Venkata Dasu, Sanjukta Patra
International Journal of Biological Macromolecules.2024; 277: 133951. CrossRef

Diabetes, obesity and metabolism
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem: Jung-Hwan Cho, Sunghwan Suh; Endocrinol Metab. 2024;39(2):222-238. Published online March 27, 2024; DOI: https://doi.org/10.3803/EnM.2024.1951

65,167 View
1,848 Download
39 Web of Science
45 Crossref

Abstract PDF PubReader ePub

Glucocorticoids provide a potent therapeutic response and are widely used to treat a variety of diseases, including coronavirus disease 2019 (COVID-19) infection. However, the issue of glucocorticoid-induced hyperglycemia (GIH), which is observed in over one-third of patients treated with glucocorticoids, is often neglected. To improve the clinical course and prognosis of diseases that necessitate glucocorticoid therapy, proper management of GIH is essential. The key pathophysiology of GIH includes systemic insulin resistance, which exacerbates hepatic steatosis and visceral obesity, as well as proteolysis and lipolysis of muscle and adipose tissue, coupled with β-cell dysfunction. For patients on glucocorticoid therapy, risk stratification should be conducted through a detailed baseline evaluation, and frequent glucose monitoring is recommended to detect the onset of GIH, particularly in high-risk individuals. Patients with confirmed GIH who require treatment should follow an insulin-centered regimen that varies depending on whether they are inpatients or outpatients, as well as the type and dosage of glucocorticoid used. The ideal strategy to maintain normoglycemia while preventing hypoglycemia is to combine basal-bolus insulin and correction doses with a continuous glucose monitoring system. This review focuses on the current understanding and latest evidence concerning GIH, incorporating insights gained from the COVID-19 pandemic.

Citations

Citations to this article as recorded by

Sepsis-associated encephalopathy: Unraveling molecular mechanisms, emerging therapeutics, and translational frontiers
Xinlong Zhang, Kaizong Huang, Zixin Wu, Rui Ding, Junming Han, Yuan Zhang, Yaping Lu, Yingmei Lu, Yanna Si
Pharmacology & Therapeutics.2026; 278: 108971. CrossRef
Nutritional modulation of biochemical pathways in stress response: A comprehensive review
Sandra Ajiroghene Gometi, Daniel Oghenerurie Ikpahwore, Uduenevwo Francis Evuen, Mercy Ogheneruno Omo-Okoroh, Ejohwomu Joe Otovbo, Prosper Chinyelum Okwuenu, Abigail Okezi Isoje, Iruoghene Onosakponome
Food and Humanity.2026; 6: 101017. CrossRef
Insulin Resistance in Systemic Sclerosis: Decoding Its Association with Severe Clinical Phenotype
Eugenio Capparelli, Luca Clerici, Giusy Cinzia Moltisanti, Francesco Lapia, Eleonora Zaccara, Francesca Capelli, Daniela Bompane, Maria Sole Chimenti, Sergio Finazzi, Paola Maria Luigia Faggioli, Antonino Mazzone
Journal of Clinical Medicine.2026; 15(2): 774. CrossRef
Increased incidence of diabetes mellitus in hematological malignancies: a systematic review and meta-analysis
Zahra Moradi, Samaneh Toutounchian, Anahita Akhiani, Hannaneh Razaghi, Mohammad Ali Mamdooh, Parmida Bagheri, Maryam Barkhordar, Zahra Salehi
BMC Cancer.2026;[Epub] CrossRef
Synergistic Efficacy of Lactobacillus plantarum Supernatant-Preconditioned BM-MSCs in Alleviating Depression, Anxiety-Like Behavior, and Memory Impairment in a Rat Stress Model by Suppressing the NF-κB Pathway
Mohammad Amini, Elahe Motevaseli, Maryam Zahmatkesh, Zahra Yousefi, Elham Esmaeil-Jamaat, Gholamreza Hassanzadeh, Tahmineh Mokhtari
Molecular Neurobiology.2026;[Epub] CrossRef
Pathogenic analysis of post-transplantation obesity: A comprehensive systematic review
Ke-Ran Chen, Lin-Zhi Wu, Yi-Ning Huang, Si-Yu Zhuang, Ze-Yu Chen, Bin Xu, Tian-Cheng Xu
World Journal of Transplantation.2026;[Epub] CrossRef
Glucocorticoid-Induced Hyperglycemia in Patients With Cancer: Mechanisms, Clinical Implications, and Management Strategies
Luana Lury Morikawa, Marcia Nery, Marcos Tadashi Kakitani Toyoshima
Endocrine Practice.2026;[Epub] CrossRef
The Hidden Burden
Harinder Dosanjh Raipuria, Catherine M. Gordon
Advances in Pediatrics.2026;[Epub] CrossRef
The impact of COVID-19 illness on metabolic phenotypes underlying type 2 diabetes mellitus: a systematic review
Michelle Li, Kaylem Sharma, Ji-Eun Chon, Nagam Anna Yehia, Ravi Retnakaran, Stewart B. Harris, Anthony J. Hanley
Diabetes Research and Clinical Practice.2026; 235: 113163. CrossRef
Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review
Aleksandra Jędrasek, Karolina Lisowska, Leszek Czupryniak
Frontiers in Clinical Diabetes and Healthcare.2026;[Epub] CrossRef
Correlation analysis of blood glucose elevation following glucocorticoid treatment in children with pneumoniae pneumonia and levels of miR-21, miR-221, and T-Lymphocyte subsets
Xue Yao, Yang Kang, Minghui Bai, Linbo Fan, Xing Wang
Heart & Lung.2026; 79: 102792. CrossRef
Glucocorticoid‐Induced Hyperglycaemia in Hospital: The Insulin Dose Matters Most
Morton G. Burt, Faran Khalili, Anjana Radhakutty, Angela X. Chen
Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Coexisting Asthma and Diabetes Are Associated With Adverse Metabolic and Inflammatory Profiles
Sixtus Aguree, Patricia Silveyra, Nianjun Liu, Arthur H. Owora, Tesfaye B. Mersha
Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Clinical and biochemical changes during high-dose glucocorticoid therapy in patients with pemphigus vulgaris (a comparative study with endogenous hypercortisolism)
Nataliia A. Budul, Vladislava O. Kornushenko, Irina V. Komerdus, Anton V. Molochkov, Oleg V. Karzanov, Yulia A. Dodrovolnaya, Irena A. Ilovayskaya
Almanac of Clinical Medicine.2026; 53(6): 315. CrossRef
Diabetes and cancer: glucose control impact on survival and tumor outcomes
Rosaria Maddalena Ruggeri, Erika Maria Grossrubatscher, Giulia Arrivi, Eleonora Ciocca, Alessia Filice, Bianca Golisano, Rossella Mazzilli, Natalie Prinzi, Annamaria Colao, Antongiulio Faggiano
Reviews in Endocrine and Metabolic Disorders.2026;[Epub] CrossRef
20(R)-Rg3 derived from ginseng fibrous roots ameliorates DSS-induced colitis via selective modulation of glucocorticoid receptor signaling
Xinyu Kong, Pei Wang, Shumin Zhang, Lijuan Kou, Mengxia Tan, Zeping Xie, Wei Guo
Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub] CrossRef
Association analysis and exploratory mediation study of the stress-induced hyperglycaemia ratio and glycaemic ratio indices with diabetic retinopathy in patients with type 2 diabetes
Deyuan Zhang, Zhongyuan Jia, Anyi Geng, Zhihua Zhang, Xiaoyu Pan, Xing Zhong
Frontiers in Nutrition.2026;[Epub] CrossRef
Minimal change disease in a patient with type 1 diabetes and Crohn’s disease managed with advanced hybrid closed-loop insulin therapy during corticosteroid treatment
Atsushi Sato, Nozomi Harai, Ryutaro Fumoto, Yuya Suzuki, Takayasu Uchida, Kimio Matsumura, Yusuke Yokoyama, Akinari Sekine, Akira Matsui, Kei Kono, Yutaka Takazawa, Kenichi Ohashi, Kaoru Nagasawa, Yasumichi Mori
Diabetology International.2026;[Epub] CrossRef
The roles, mechanisms, and therapeutic implications of glucocorticoids in glucose and lipid metabolism
Qiu-Yu Xu, Jie Zhang, Xin-Jian Wan, Ling Wu, Ji-Chun Yang, Yan Lu
Military Medical Research.2026; 13(1): 100037. CrossRef
Quercetin inhibits steroid-induced hypergluconeogenesis in Saccharomyces cerevisiae
Victor Arokia Doss, Gowtham Subramaniam, Keerthana Manoharan
Future Journal of Pharmaceutical Sciences.2025;[Epub] CrossRef
Complications related to oral corticosteroid use in asthma patients: a retrospective cohort study
Chih-Cheng Lai, Chao-Hsien Chen, Ya-Hui Wang, Cheng-Yi Wang, Hao-Chien Wang
Expert Review of Clinical Pharmacology.2025; 18(4): 225. CrossRef
The presumable combined effects of hydroxychloroquine and its metabolites on the blood lipids and glucose in the treatment of rheumatoid arthritis
Huaixuan Zhang, Xueting Wu, Yue Wang, Zhongling Yang, Yaqian Dai, Zongwen Shuai
Inflammopharmacology.2025; 33(5): 2769. CrossRef
Inhalable multilevel responsive microspheres for radiation-induced lung injury
Xinlian Wang, Jinhui Lin, Dongtao Yin, Xin Li, Zhichen Lang, Guanghui Zhang, Yueguang Xue, Shilin Li, Xiao Zhang, Bing Han, Fengsheng Li, Ying Liu
Nano Research.2025; 18(5): 94907339. CrossRef
Add-On Treatment with Gliclazide for Cancer Patients with Type 2 Diabetes Undergoing Cyclic Glucocorticoid-Containing Chemotherapy
Seung Eun Lee, Ju-Hyun Park, Dalyong Kim, Hyun-A Lee, Yun Seong Kang, Young Soon Yoon, Yun Jeong Jeong, Han Seok Choi, Kyoung-Ah Kim
Biomedicines.2025; 13(5): 1101. CrossRef
Bioengineered platelet nanoplatform enables renal-targeted dexamethasone delivery for chronic nephritis therapy with dual anti-inflammatory/anti-fibrotic effects and minimized systemic toxicity
Lingling Zhang, Haifeng Gong, Xuelian Gong, Bing Zhou, Xijian Wang, Shengnan Fei, Donglin Xia, Chunyang Xu, Xinzhong Huang
Bioactive Materials.2025; 52: 213. CrossRef
Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer
Sophie R. Ulene, Shikun Wang, Joshua R. Cook, Fiona McAuley, Margaux E. Wooster, Khadija F. Faheem, Andrew Varoli, Julia E. McGuinness, Neil Vasan, Meghna S. Trivedi, Katherine D. Crew, Erik Harden, Cynthia Law, Dawn L. Hershman, Melissa K. Accordino
Breast Cancer Research and Treatment.2025; 212(3): 511. CrossRef
Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders
Maria-Zinaida Dobre, Bogdana Virgolici, Ruxandra Cioarcă-Nedelcu
Current Issues in Molecular Biology.2025; 47(7): 565. CrossRef
Dapagliflozin prevents glucocorticoid‐induced hyperglycaemia: Results from the DAPACOID Phase II Clinical Trial
Erick Josefat Díaz Huerta, German Duarte Bojórquez, Citlali Guadalupe Hernández Guzmán, Oscar Noel Chávez Hernández, Claudia Zepeda Moreno, Verónica Edith Velázquez Díaz, Eréndira Pacheco Zavala, Benjamín Sandoval Pérez, Alejandra Alvarez Salinas, Lauro F
Diabetes, Obesity and Metabolism.2025; 27(10): 6050. CrossRef
New-onset diabetes mellitus post COVID-19 infection: a systematic review and meta-analysis
Emma Cocking, Joseph Daher, Majid Alabbood
Diabetes Research and Clinical Practice.2025; 227: 112417. CrossRef
Managing Adverse Effects Associated with Long-Term Glucocorticoid Use
Mi Kyung Kim
The Korean Journal of Medicine.2025; 100(4): 158. CrossRef
Long-Term Neuroimaging Findings in a Murine Model of Human Extraparenchymal Neurocysticercosis
Alejandro Méndez, Agnes Fleury, Roger Carrillo-Mezo, Juan A. Hernández-Aceves, Montserrat Mejía-Hernández, Nelly Villalobos, Marisela Hernández, Raúl Bobes, Luis Concha, Juan J. Ortiz-Retana, Marta Romano, Pedro Tadao Hamamoto Filho, Gladis Fragoso, José
ACS Infectious Diseases.2025; 11(9): 2534. CrossRef
Impact of long-acting glucocorticoids on ICU mortality in septic patients with acute respiratory failure: a MIMIC-IV based cohort study
Yanhui Deng, Shaoxiang Wang, Shaohua Zhou, Wan Zhao, Aitian Wang, Jingli Gao
Frontiers in Pharmacology.2025;[Epub] CrossRef
The impact of diabetes and obesity on the severity and mortality of SARS-CoV-2 infection
Tomasz Klaudel, Michał Pelczarski, Monika Zaborska, Jakub Sadowski, Samanta Anna Ostrowska, Adam Drzymała, Rafał Jakub Bułdak
Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Emerging applications of nanotechnology in the treatment of acute kidney injury
Lingxue Zeng, Jonghan Kim, Hak Soo Choi, Michael P. Hutchens
Nanomedicine.2025; 20(21): 2661. CrossRef
Distinct microbial and metabolic shifts characterize acute coronary syndrome and recovery
Jing Xu, Die Dai, Yanan Yang, Shanshan Gao, Jingang Yang, Chaoran Dong, Weixian Yang, Jiansong Yuan, Tianjie Wang, Tao Tian, Yanmin Yang, Fang Luo, Ping Jiang, Chao Wu, Xiaolu Sun, Yonggang Sui, Guofeng Gao, Wentao Ma, Yuan Wu, Jun Zhang, Jia Li, Chao Guo
iMeta.2025;[Epub] CrossRef
The importance of glycemic status in burn patients’ outcomes
Haniyeh Sadat Fayazi
Burns.2025; 51(9): 107716. CrossRef
PROTOCOL: New‐Onset Diabetes Mellitus Post COVID‐19 Infection: A Systematic Review and Meta‐Analysis
Emma Cocking, Joseph Daher, Majid Alabbood
Campbell Systematic Reviews.2025;[Epub] CrossRef
The impact of the COVID-19 pandemic on the global burden of type 2 diabetes: a study based on GBD 2021 data
Xiaoqin Chen, Hui Lin, Yinlian Wu, Mingfang Wang, Su Lin, Jiaofeng Huang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Balancing benefit and risk: clinical considerations in the use of acetaminophen, non-steroidal anti-inflammatory drugs, and dexamethasone for perioperative multimodal analgesia
Boohwi Hong, Woosuk Chung, Chahyun Oh
The Korean Journal of Pain.2025; 38(4): 364. CrossRef
Advances in anthocyanin nanoparticle delivery systems in anti-inflammatory therapies
Hanchi Zhang, Xinrui Qi, Lin Yang, Panpan Xia, Jitao Ling, Xuehong Zheng, Jianqi Liang, Pingping Yang, Yixuan Chen, Xiao Liu, Deju Zhang, Yaqi Rong, Caiwei Chen, Jing Zhang, Peng Yu, Yiming Gan
Pharmacological Research.2025; 222: 108038. CrossRef
Thyrotoxic Hypokalemic Periodic Paralysis: Pathophysiological Mechanisms
Gan Qing, Wan Nur Amalina Zakaria, Fatimah Zahra Mohamad Rom, Wan Nor Fazila Hafizan Wan Nik, Hani Ajrina Zulkeflee, Siti Nadirah Ab Rahim
Endocrinology and Metabolism.2025; 40(6): 821. CrossRef
Steroid-Induced Hyperglycaemia in a Patient With Possible Body Dissatisfaction: A Case Report
Chukwuebuka E Ohakpougwu, Wendy M Bebobru, Emmanuel Labram
Cureus.2025;[Epub] CrossRef
Cigarette Smoking-Induced Glucose Metabolic Reprogramming in Chronic Obstructive Pulmonary Disease: Mechanisms and Therapeutic Implications
Tingfen Ji, Yang-Yang Gu, Ying-Man Gao, Ying Xie, Zhao Liu, Anqi Cheng, Xinmei Zhou, Aihemaiti Ailifeire, Min Wang, Qingqing Song, Yuxin Shi, Shunyi Shi, Jiahui He, Liang Zhao, Dan Xiao, Chen Wang
International Journal of Chronic Obstructive Pulmonary Disease.2025; Volume 20: 3855. CrossRef
Effect of hypoglycemic events on cognitive function in individuals with type 2 diabetes mellitus: a dose–response meta-analysis
Min Ye, Qiqi Yang, Lele Zhang, Hudie Song, Qin Fu, Jun Qian, Hongyu Xie, Aihong Yuan
Frontiers in Neurology.2024;[Epub] CrossRef
Diabetes and the associated complications: The role of antioxidants in diabetes therapy and care
Lowell Dilworth, Dewayne Stennett, Aldeam Facey, Felix Omoruyi, Shada Mohansingh, Felix O. Omoruyi
Biomedicine & Pharmacotherapy.2024; 181: 117641. CrossRef

Original Article

Diabetes, obesity and metabolism
Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis: A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta, Shahjada Selim; Endocrinol Metab. 2024;39(1):109-126. Published online January 23, 2024; DOI: https://doi.org/10.3803/EnM.2023.1839

11,530 View
192 Download
21 Web of Science
21 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
No recent meta-analysis has holistically analyzed and summarized the efficacy and safety of omarigliptin in type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to address this knowledge gap.
Methods
Electronic databases were searched to identify randomized controlled trials (RCTs) that included patients with T2DM who received omarigliptin in the intervention arm. The control arm consisted of either a placebo (passive control group [PCG]) or an active comparator (active control group [ACG]). The primary outcome assessed was changes in hemoglobin A1c (HbA1c), while secondary outcomes included variations in glucose levels, achievement of glycemic targets, adverse events (AEs), and hypoglycemic events.
Results
From 332 initially screened articles, data from 16 RCTs involving 8,804 subjects were analyzed. Omarigliptin demonstrated superiority over placebo in reducing HbA1c levels (mean difference, –0.58%; 95% confidence interval, –0.75 to –0.40; P<0.00001; I²=91%). Additionally, omarigliptin outperformed placebo in lowering fasting plasma glucose, 2-hour postprandial glucose, and in the percentage of participants achieving HbA1c levels below 7.0% and 6.5%. The glycemic efficacy of omarigliptin was similar to that of the ACG across all measures. Although the omarigliptin group experienced a higher incidence of hypoglycemic events compared to the PCG, the overall AEs, serious AEs, hypoglycemia, and severe hypoglycemia were comparable between the omarigliptin and control groups (PCG and ACG).
Conclusion
Omarigliptin has a favorable glycemic efficacy and safety profile for managing T2DM.

Citations

Citations to this article as recorded by

Effectiveness and Safety of Once-Weekly Trelagliptin versus Daily DPP-4 Inhibitors in Fasting People with Type 2 Diabetes during Ramadan
Sanobia Yousuf, Muhammad Yakoob Ahmedani
Journal of Diabetes and Endocrine Practice.2026;[Epub] CrossRef
Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Shahjada Selim, Faria Afsana, Lakshmi Nagendra, Rezwana Ahmed, Deep Dutta
Endocrine Practice.2025; 31(3): 315. CrossRef
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Manoj Kumar, A.B.M. Kamrul-Hasan, Saptarshi Bhattacharya
Endocrine Practice.2025; 31(4): 471. CrossRef
Neuropsychiatric Effects of Tirzepatide: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Sanja Borozan, Deep Dutta, Lakshmi Nagendra, Dina Shrestha, Joseph M. Pappachan
Endocrine Practice.2025; 31(5): 703. CrossRef
Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis
A B M Kamrul-Hasan, Shinjan Patra, Deep Dutta, Lakshmi Nagendra, AFM Muntahi-Reza, Sanja Borozan, Joseph M Pappachan
World Journal of Diabetes.2025;[Epub] CrossRef
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta, Thanikai Sasikanth, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra
Endocrinology and Metabolism.2025; 40(1): 112. CrossRef
Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis
Abul Bashar Mohammad Kamrul-Hasan, Joseph M Pappachan, Deep Dutta, Lakshmi Nagendra, Mohammad Shafi Kuchay, Nitin Kapoor
World Journal of Diabetes.2025;[Epub] CrossRef
Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis
Abul Bashar Mohammad Kamrul-Hasan, Vanishri Ganakumar, Lakshmi Nagendra, Deep Dutta, M Rafiqul Islam, Joseph M Pappachan
World Journal of Diabetes.2025;[Epub] CrossRef
Omarigliptin ameliorates cisplatin-induced renal damage: Cross-talk between glucagon-like peptide-1, HMGB1/RAGE/TLR4 signaling, and TXNIP/NLRP3 inflammasome/gasdermin D axis
Shuruq E. Alsufyani, Hany H. Arab, Azza A.K. El-Sheikh, El-Shaimaa A. Arafa, Ahmed Fouad Hussein Hashad, Reham M. Goda, Tamer M. Naguib, Maaly A. Abd Elmaaboud, Mennatallah A. Elkady, Ahmed M. Kabel
Life Sciences.2025; 376: 123758. CrossRef
Trabecular Bone Score in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Saptarshi Bhattacharya, Vanishri Ganakumar, Lakshmi Nagendra, Deep Dutta, Fatema Tuz Zahura Aalpona, Joseph M. Pappachan
Journal of Clinical Densitometry.2025; 28(4): 101602. CrossRef
Thrice-Weekly Insulin Degludec Versus Once-Daily Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Sanja Borozan, Cornelius J Fernandez, Deep Dutta, Lakshmi Nagendra, Joseph M Pappachan
British Journal of Hospital Medicine.2025; 86(7): 1. CrossRef
Prevalence of diabetes distress among people with type 2 diabetes in South Asia: A systematic review and meta-analysis
Abul Bashar Mohammad Kamrul-Hasan, Joseph M Pappachan, Lakshmi Nagendra, Dimuthu Muthukuda, Deep Dutta, Saptarshi Bhattacharya, Dina Shrestha, Guru Prasad Dhakal, Manilka Sumanatilleke, Syed Abbas Raza, Sanjay Kalra
World Journal of Diabetes.2025;[Epub] CrossRef
Role of automated insulin delivery in managing insulin-treated outpatients with type 2 diabetes: A systematic review and meta-analysis
Abul Bashar Mohammad Kamrul-Hasan, Joseph M Pappachan, Lakshmi Nagendra, Nazma Akter, Sweekruti Jena, Deep Dutta, Sunil Nair
World Journal of Diabetes.2025;[Epub] CrossRef
Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis
Abul Bashar Mohammad Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sindhu Doddabokikere Basavarajappa, Harish Bukkasagar Girijashankar, Ameya Joshi, Joseph M Pappachan
World Journal of Diabetes.2025;[Epub] CrossRef
Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis
A.B.M. Kamrul-Hasan, Mohammad Abdul Hannan, Muhammad Shah Alam, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra, Shahjada Selim, Deep Dutta
Medicine.2024; 103(25): e38592. CrossRef
Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy
Ashraf Al Madhoun
World Journal of Diabetes.2024; 15(8): 1654. CrossRef
Inhibition of Oxidative Stress and Related Signaling Pathways in Neuroprotection
Maja Jazvinšćak Jembrek
Antioxidants.2024; 13(9): 1033. CrossRef
Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sunetra Mondal, Saptarshi Bhattacharya, Sanjay Kalra
Endocrine Practice.2024; 30(11): 1103. CrossRef
Hepatobiliary effects and safety of tirzepatide: A systematic review and meta‐analysis
A. B. M. Kamrul‐Hasan, Deep Dutta, Lakshmi Nagendra, Mohammad Shafi Kuchay, Md. Saiful Islam, Joseph M. Pappachan
Diabetes, Obesity and Metabolism.2024; 26(12): 6074. CrossRef
Efficacy and Safety of Ertugliflozin Compared to Placebo in Patients With Type 2 Diabetes: An Updated Systematic Review and Meta‐Analysis
A. B. M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Mohammad Abdul Hannan, Deep Dutta, Lakshmi Nagendra, Shahjada Selim, Eusebio Chiefari
Journal of Diabetes Research.2024;[Epub] CrossRef
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
A. B. M. Kamrul‐Hasan, Sunetra Mondal, Deep Dutta, Lakshmi Nagendra, Mohammed Ruhul Kabir, Joseph M. Pappachan
Obesity Science & Practice.2024;[Epub] CrossRef

Review Article

Adrenal gland
The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin: Eline C. Nijenhuis-Noort, Kirsten A. Berk, Sebastian J. C. M. M. Neggers, Aart J. van der Lely; Endocrinol Metab. 2024;39(1):83-89. Published online January 9, 2024; DOI: https://doi.org/10.3803/EnM.2024.101

156,452 View
1,499 Download
48 Web of Science
51 Crossref

Abstract PDF PubReader ePub

This review intends to provide the reader with a practical overview of several (patho)physiological conditions in which knowledge of the interplay between growth hormone (GH), insulin-like growth factor-1 (IGF-1), and insulin is important. This might help treating physicians in making the right decisions on how to intervene and improve metabolism for the benefit of patients, and to understand why and how metabolism responds in their specific cases. We will specifically address the interplay between GH, IGF-1, and insulin in type 1 and 2 diabetes mellitus, liver cirrhosis, and acromegaly as examples in which this knowledge is truly necessary.

Citations

Citations to this article as recorded by

Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Ruth Frampton, Samantha Hocking, Jennifer R. Snaith, Jerry R. Greenfield
Trends in Endocrinology & Metabolism.2026; 37(2): 135. CrossRef
Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review
Seyed Mostafa Rahimi, Abouzar Bagheri
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(3): 3335. CrossRef
Zhi-Shen Pill ameliorates impaired glucose tolerance by targeting pancreatic β-cell and adipocyte pathways
Yinshan Huang, Xuan Ren, Xiudao Song, Kaiwen Xu, Lijuan Jin, Hui Zhu, Wei Chen, Wei Mu, Chunbo Jiang, Guoqiang Liang
Journal of Ethnopharmacology.2026; 357: 120931. CrossRef
Human growth hormone‐induced mitotic maladaptation in podocytes and implications in diabetic kidney disease
Bharath Banoth, Sumathi Raviraj, Anil Kumar Pasupulati
Journal of Neuroendocrinology.2026;[Epub] CrossRef
Dairy intake and risk of type 2 diabetes and metabolic syndrome: A narrative review
Karani Santhanakrishnan Vimaleswaran, Viswanathan Mohan
Nutrition.2026; 144: 113064. CrossRef
Maternal diet shapes milk bile acids to regulate neonatal growth through TGR5
Lufuno Phophi, Haley M. Wilt, Zhengzheng Hu, Rishi Gadikota, Mallory Cadiz, Mikayla S. Manzi, Freddie D. Ortiz Martinez, Sarayu Vanga, Elizabeth G. Chapman, Scott A. Tibbetts, Stephanie M. Karst
Cell Reports.2026; 45(1): 116744. CrossRef
Dietary Defective Jujube as a Corn Substitute: Impacts on Growth Performance, Meat Traits, and Alternaria Toxin Exposure in Lambs
Letian Zhang, Haoyang Hui, Muhammad Faheem, Yanfeng Xue, Ning Chen, Xiaoling Zhou
Animals.2026; 16(2): 255. CrossRef
Insulin Receptor Family Autoantibodies in Patients with Type B Insulin Resistance
Jennifer E Lee, Thilo S Chillon, Waldemar B Minich, Brent S Abel, Marissa Lightbourne, Lutz Schomburg, Rebecca J Brown
The Journal of Clinical Endocrinology & Metabolism.2026; 111(6): e1506. CrossRef
The relationship between IGF-1 and cardiovascular diseases and the potential mediating role of TyG-related index: evidence from a cohort study
Haipeng Chen, Ning Huang, Yang Huang, Jin Chen, Xu Luo
BMC Cardiovascular Disorders.2026;[Epub] CrossRef
IGF-1 as a mediator in the association between body mass index and risk of liver cancer: A prospective analysis of 432,203 participants from the UK biobank
Wenwen Yang, Zhixian Bao, Yuhua Chen, Jie Gao, Rui Ji
Growth Hormone & IGF Research.2026; 84: 101684. CrossRef
Associations of insulin-like growth factor 1 and IGF binding proteins 2 and 3 with lipids in toddlers
Johanna Neiß, Hans Demmelmair, Fabian Geyer, Alexander Triebswetter, Dudung Angkasa, Joaquin Escribano, Natalia Ferré, Mariona Gispert-Llauradó, Berthold Koletzko, Susanne Bechtold-Dalla Pozza, Veit Grote
Lipids in Health and Disease.2026;[Epub] CrossRef
Mechanisms in diabetes mellitus: Relationships to metabolism and/or neoplasia
John A. D'Elia, Bijan Roshan, Larry A. Weinrauch
Journal of Diabetes and its Complications.2026; 40(4): 109289. CrossRef
Corrigendum to ‘What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?’ [JDC, Vol. 39, Issue 10, October 2025, 109132]
Maria Aurora Roma-Wilson, Paolo Pozzilli
Journal of Diabetes and its Complications.2026; 40(3): 109230. CrossRef
Maternal Bacillus probiotic regulates offspring growth and immunity via spleen IGF-1/mTOR and FOXO1/IL-10 pathways
Tahany Saleh Aldayel, Heba M. A. Abdelrazek, Nadia A. El-Fahla, Noran M. Tawfik, Dalia A. Eltamany, Dalia W. Zeidan, Sherine Abbas
Scientific Reports.2026;[Epub] CrossRef
Multi-omic analysis of the liver-breast axis reveals key hepatic mediators of breast cancer progression
Gao Yuanze, Fei Wang, Kumar Ganesan, Jianping Chen
Science China Life Sciences.2026;[Epub] CrossRef
Metformin inhibits PDGFβ signaling to suppress hyaluronan and cytokine production in thyroid eye disease
Farha Husain, Charkira C. Patrick, Elisa Roztocil, Steven E. Feldon, Collynn F. Woeller
Experimental Eye Research.2026; 267: 110982. CrossRef
A one-week reduced-carbohydrate diet lowers insulin requirements and shifts the IGF axis with no detectable short-term change in endothelial function in a randomized, crossover trial of adults with type 1 diabetes
M. Naweed Akbar, T. Jordan Smith, Sivaprakasam Chinnarasu, Wendi Welch, Wang Zuofei, Bridget Litts, Lauren M. LeStourgeon, Mohammad Saleem, Mohd Mabood Khan, Annet Kirabo, Justin M. Gregory
Cardiovascular Diabetology – Endocrinology Reports.2026;[Epub] CrossRef
Teprotumumab N01 for thyroid eye disease in China: clinical outcomes and quantitative MRI correlations
Qiuyu Wang, Junning Cheng, Chunhui Yang, Jian Song, Yuqing Chen, Ya Shen, Lefeng Qu, Ruili Wei
Frontiers in Medicine.2026;[Epub] CrossRef
Association between disease duration, GH-IGF-1 axis markers, and linear growth in children with type 1 diabetes mellitus: a cross-sectional study
Feruzakhan Uvaidillaeva, Rustam Tukhvatshin, Valeriia Kniazeva, Baktygul Omurkulova
Heart, Vessels and Transplantation.2026;[Epub] CrossRef
Beyond Deterministic Fetal Programming: Intrauterine Exposures and the Multifactorial Origins of Adiposity
Gernot Desoye, Ursula Hiden, Evelyn Jantscher‐Krenn, Herbert Fluhr, Jonathan C. Wells, Sonja Entringer, Mireille N. M. van Poppel
Obesity Reviews.2026;[Epub] CrossRef
Nutritional Status of Children with Short Stature Is Oppositely Associated with Growth Hormone Peak in Stimulation Tests and Insulin-like Growth Factor-1 Concentration
Joanna Smyczyńska, Urszula Smyczyńska, Maciej Hilczer, Renata Stawerska
Journal of Clinical Medicine.2026; 15(9): 3333. CrossRef
Association Between Uncontrolled Type 2 Diabetes mellitus and Concentrated Growth Factor Composition: A Cross-Sectional Study
Shakila Mahesh, Alpa Gupta, Rajat Sharma, Meenu Tawatia
Journal of International Society of Preventive and Community Dentistry.2026;[Epub] CrossRef
Insulin-Like Growth Factor Signaling in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies
Jie Miao, Yanli Zhang, Chen Su, Qiandan Zheng, Junhong Guo
Molecular Neurobiology.2025; 62(3): 3195. CrossRef
GHRH in diabetes and metabolism
Charlotte Steenblock, Stefan R. Bornstein
Reviews in Endocrine and Metabolic Disorders.2025; 26(3): 413. CrossRef
Signaling pathways and targeted therapies in Ewing sarcoma
Ke Jia, Li Cao, Yihan Yu, Doudou Jing, Wei Wu, Brian Andrew Van Tine, Zengwu Shao
Pharmacology & Therapeutics.2025; 266: 108765. CrossRef
Expanding the Clinical and Mutational Spectrum of Biallelic POC1A Variants: Characterization of Four Patients and a Comprehensive Review of POC1A‐Related Phenotypes
Umut Altunoglu, Gozde Tutku Turgut, Esin Karakılıç Özturan, Tuğba Kalaycı, Mert Kaya, Güven Toksoy, Firdevs Baş, Hülya Kayserili, Feyza Darendeliler
Clinical Genetics.2025; 107(4): 390. CrossRef
Bridging Pubertal Changes and Endotype Based Therapy in Type 1 Diabetes
M. A. Roma‐Wilson, R. Buzzetti, S. Zampetti
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
Training with electrical muscle stimulation: a novel method to improve Body Mass Index, lipid profile, growth hormone, and cortisol in overweight subjects
Elnaz RIYAHI, Jalil REISI, Sayyed M. MARANDI, Milad ABDOLLAHI
The Journal of Sports Medicine and Physical Fitness.2025;[Epub] CrossRef
Bilateral ovarian juvenile granulosa cell tumor in a neonate with Donohue syndrome: a case report and review of literature
Amany Reda Elbahbity, Amr Abdelhamid AbouZeid, Mohammad Hassan Mohamed, Mohammad Hassan Elibiary, Soha M. khafagy, Amira Mostafa Rashad, Shaimaa Mahmoud Abdelraouf, Sohair Abdelbaset Zayed, Manal Fawzy Gadalla, Shaimaa Abdelsattar Mohammad
Egyptian Pediatric Association Gazette.2025;[Epub] CrossRef
Association of IGF-1 and IGFBP-3 with metabolic abnormalities among children and adolescents
Zhenghao Zhao, Yuanyuan Ma, Xinyi Zhang, Xiaoxiao Liu, Yang Li, Zhongze Fang, Rongxiu Zheng, Jing Li
Frontiers in Endocrinology.2025;[Epub] CrossRef
Early Cardiovascular and Metabolic Benefits of rhGH Therapy in Adult Patients with Severe Growth Hormone Deficiency: Impact on Oxidative Stress Parameters
Maria Kościuszko, Angelika Buczyńska, Justyna Hryniewicka, Dorota Jankowska, Agnieszka Adamska, Katarzyna Siewko, Małgorzata Jacewicz-Święcka, Marcin Zaniuk, Adam Jacek Krętowski, Anna Popławska-Kita
International Journal of Molecular Sciences.2025; 26(12): 5434. CrossRef
Effects of warm-season feeding on yak growth, antioxidant capacity, immune function, and fecal microbiota
Yining Xie, Yangji Cidan, Zhuoma Cisang, Deji Gusang, Quzha Danzeng, Wangdui Basang, Yanbin Zhu, Jinshui Lin, Lizhuang Hao, Tariq Shah
Microbiology Spectrum.2025;[Epub] CrossRef
Post-Exercise Whey Protein Supplementation: Effects on IGF-1, Strength, and Body Composition in Pre-Menopausal Women, a Randomised Controlled Trial
Marc Murray, Lara Vlietstra, Alyssa M. D. Best, Stacy T. Sims, James A. Loehr, Nancy J. Rehrer
Nutrients.2025; 17(12): 2033. CrossRef
Diagnostic accuracy of triglyceride to glucose index and triglyceride/high-density lipoprotein index for insulin resistance among children and adolescents: A systematic review
Miguel Cabanillas-Lazo, Carlos Quispe-Vicuña, Milagros Pascual-Guevara, Claudia Cruzalegui-Bazán, Arturo Duran-Pecho, José Paz-Ibarra, Victor Velásquez-Rimachi, Qian Wu
PLOS One.2025; 20(6): e0326179. CrossRef
Diabetes and Bone Health: A Comprehensive Review of Impacts and Mechanisms
Prabhat Upadhyay, Sudhir Kumar
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
High Blood Lead Levels as A Risk Factor of Stunting: A Study of Children in Agricultural Areas
Alfan Afandi, Suhartono Suhartono, Budiyono Budiyono, Ani Margawati, Apoina Kartini
JURNAL KESEHATAN LINGKUNGAN .2025; 17(1): 45. CrossRef
Viral Infections in Type 2 Diabetes: A Dangerous Liaison
Azizul Haque, Anudeep B. Pant
Viruses.2025; 17(9): 1150. CrossRef
Intranasal nanoparticle therapy for arsenic-induced neurotoxicity: Restoring IGF-1 signaling and advancing translational neuroprotection
Nourhan Elsayed, Jhi Biau Foo
Neuroscience.2025; 585: 107. CrossRef
Serum IGF-1 May be less reliable when assessing the GH-IGF-1 axis in the elderly
Angelo Milioto, Gudmundur Johannsson, Daniela Esposito
Pituitary.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
Ralf Weiskirchen, Amedeo Lonardo
International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Regenerative therapeutic effects of conditioned medium from human umbilical cord‑derived mesenchymal stem cells as an adjuvant to insulin therapy in a rat model of type 2 diabetes
Siufui Hendrawan, Jennifer Lheman, Olivia Marcelina, Lydia Tantoso, Hans Baer, Shirly Gunawan
World Academy of Sciences Journal.2025; 7(6): 1. CrossRef
Prevalence of Liver Steatosis and Fibrosis Assessed by Transient Elastography in a High Cardiovascular-Risk Outpatient Cohort Including T1DM and T2DM Patients
Alina N. Saidi, Willy B. Theel, Diederick E. Grobbee, Aart-Jan van der Lely, Femme Dirksmeier-Harinck, Marco Alings, Ellen van der Zwan-van Beek, Simone P. Rauh, Moniba Rasheed, Manuel Castro Cabezas
Diabetology.2025; 6(11): 129. CrossRef
Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus
Viviana Elian, Violeta Popovici, Mihnea Ioan Nicolescu, Alexandra Maria Nicolescu, Sorina Maria Aurelian, Emma Adriana Ozon
Current Issues in Molecular Biology.2025; 47(11): 929. CrossRef
Adverse events with usage of human growth hormone: a review
Ludwik K. Branski, Sarita Thanedar, Nafis Deen, Kevin W. Cho, Gongkai Liu, Gabriel Hundeshagen, David N. Herndon, Linda E. Sousse
Discover Medicine.2025;[Epub] CrossRef
Unlocking Gut-Driven Metabolic Repair: The Role of Glucomannan Porang (Amorphophallus muelleri Blume) in Insulin Resistance and Short-Chain Fatty Acid Modulation in a Type 2 Diabetes Mellitus Rat Model
Azizah H. Safitri, Rahmata A. Sayyida, Eni Widayati, Nurina Tyagita
Tropical Journal of Natural Product Research.2025;[Epub] CrossRef
Effects of Short-Term (20-Day) Alternate-Day Modified Fasting and Time-Restricted Feeding on Fasting Glucose and IGF-1 in Obese Young Women
Dian Aristia Rachmayanti, Purwo Sri Rejeki, Raden Argarini, Hermina Novida, Sri Soenarti, Shariff Halim, Chy’as Diuranil Astrid Permataputri, Sheeny Priska Purnomo
Diseases.2025; 13(12): 390. CrossRef
Human Cancers Derived from Either Genetic or Lifestyle Factors Are Initiated by Impaired Estrogen Signaling
Zsuzsanna Suba
Cancers.2025; 18(1): 78. CrossRef
IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review
Justyna Szydlowska-Gladysz, Adrianna Edyta Gorecka, Julia Stepien, Izabela Rysz, Iwona Ben-Skowronek
International Journal of Molecular Sciences.2024; 25(7): 3966. CrossRef
Insulin resistance reduction, intermittent fasting, and human growth hormone: secondary analysis of a randomized trial
Benjamin D. Horne, Jeffrey L. Anderson, Heidi T. May, Tami L. Bair, Viet T. Le, Leslie Iverson, Kirk U. Knowlton, Joseph B. Muhlestein
npj Metabolic Health and Disease.2024;[Epub] CrossRef
Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin
Kevin C. J. Yuen, Rikke Hjortebjerg, Ashok Ainkaran Ganeshalingam, David R. Clemmons, Jan Frystyk
Frontiers in Endocrinology.2024;[Epub] CrossRef
Comprehensive Management of Diabetes Mellitus in the Elderly: A Review
Bharat Kumar, Ravi Kant, Gopal Krishana Bohra
Journal of Cardio-diabetes and Metabolic Disorders.2023; 3(2): 21. CrossRef

Original Articles

Diabetes, obesity and metabolism
Effectiveness of a Social Networking Site Based Automatic Mobile Message Providing System on Glycemic Control in Patients with Type 2 Diabetes Mellitus: Kyuho Kim, Jae-Seung Yun, Joonyub Lee, Yeoree Yang, Minhan Lee, Yu-Bae Ahn, Jae Hyoung Cho, Seung-Hyun Ko; Endocrinol Metab. 2024;39(2):344-352. Published online December 27, 2023; DOI: https://doi.org/10.3803/EnM.2023.1871

6,096 View
141 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the effectiveness of a social networking site (SNS)-based automatic mobile message providing system on glycemic control in patients with type 2 diabetes mellitus (T2DM).
Methods
A 3-month, randomized, open-label, controlled, parallel-group trial was conducted. One hundred and ten participants with T2DM were randomized to a mobile message system (MMS) (n=55) or control group (n=55). The MMS group received protocolbased automated messages two times per day for 10 weeks regarding diabetes self-management through KakaoTalk SNS messenger. The primary outcome was the difference in the change in glycated hemoglobin (HbA1c) levels (%) from baseline to week 12.
Results
HbA1c levels were more markedly decreased in the MMS group (8.4%±0.7% to 8.0%±1.1%) than in the control group (8.5%±0.8% to 8.4%±0.8%), resulting in a significant between-group difference (P=0.027). No differences were observed in changes in fasting glucose levels, lipid profiles, and the number of participants who experienced hypoglycemia, or in changes in lifestyle behavior between groups. However, the self-monitoring of blood glucose frequency was significantly increased in the MMS group compared to the control group (P=0.003). In addition, sleep duration was increased in the MMS group, but was not changed in the control group.
Conclusion
An SNS-based automatic mobile message providing system was effective in improving glycemic control in patients in T2DM. Studies which based on a more individualized protocol, and investigate longer beneficial effect and sustainability will be required in the future.

Citations

Citations to this article as recorded by

Effectiveness of text message-delivered health behaviour intervention on HbA1c change in adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials
Qiumian Hong, Xiaoying Zhang, Mengxi Guo, Zhaoyang Wen, Qing Tang, Jiali Zhou, Peige Song, Xiaolin Wei, Ning Zhang
Health Psychology Review.2026; 20(2): 386. CrossRef
Instant messaging-based digital health interventions for diabetes management: a domain-structured systematic review and meta-analysis of randomized controlled trials
Shan Chen, Emma Mirza Wati Mohamad, Arina Anis Azlan, Xixi Zhao
Frontiers in Public Health.2026;[Epub] CrossRef
Text messaging interventions are associated with reductions in HbA1c among patients with diabetes: a systematic review and meta-analysis
Neda Pirouzmand, Grace S Ko, Lucas C Godoy, Olivia Haldenby, Cynthia A Jackevicius, Ayman Jubran, Candace D McNaughton, Baiju R Shah, Maneesh Sud, Karen Tu, Dennis T Ko
BMJ Open Diabetes Research & Care.2025; 13(6): e005218. CrossRef
Effects of multimodal mobile health interventions on cardiovascular risk factor management in patients with diabetes: a systematic review and meta-analysis
Yan Zhang, Xingqi Cao, LiJuan Huang, Yue Zhu, Liying Chen
BMJ Open.2025; 15(12): e108371. CrossRef

Mineral, Bone & Muscle Big Data Articles (National Health Insurance Service Database)
Association between Smoking Status and the Risk of Hip Fracture in Patients with Type 2 Diabetes: A Nationwide Population-Based Study: Se-Won Lee, Jun-Young Heu, Ju-Yeong Kim, Jinyoung Kim, Kyungdo Han, Hyuk-Sang Kwon; Endocrinol Metab. 2023;38(6):679-689. Published online December 6, 2023; DOI: https://doi.org/10.3803/EnM.2023.1760

7,868 View
107 Download
2 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Limited longitudinal evidence exists regarding the potential association between smoking status and hip fracture among individuals with type 2 diabetes. We investigated this association using large-scale, nationwide cohort data for the Korean population.
Methods
This nationwide cohort study included 1,414,635 adults aged 40 and older who received Korean National Health Insurance Service health examinations between 2009 and 2012. Subjects with type 2 diabetes were categorized according to their smoking status, amount smoked (pack-years), number of cigarettes smoked per day, and duration of smoking. The results are presented as hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between smoking status parameters and risk of hip fracture in multivariable Cox proportional hazard regression analysis.
Results
Compared with never-smokers, an increased adjusted HR (aHR) for hip fracture was observed in current smokers (1.681; 95% CI, 1.578 to 1.791), and a comparable aHR for hip fracture was found in former smokers (1.065; 95% CI, 0.999 to 1.136). For former smokers who had smoked 20 pack-years or more, the risk was slightly higher than that for never-smokers (aHR, 1.107; 95% CI, 1.024 to 1.196). The hip fracture risk of female former smokers was similar to that of female current smokers, but the hip fracture risk in male former smokers was similar to that of male never-smokers.
Conclusion
Smoking is associated with an increased risk of hip fracture in patients with type 2 diabetes. Current smokers with diabetes should be encouraged to quit smoking because the risk of hip fracture is greatly reduced in former smokers.

Citations

Citations to this article as recorded by

Hip fractures and type 2 diabetes in the elderly: Risk factors analysis of the Nedices cohort
Federico Hawkins Carranza, Cristina Martín-Arriscado Arroba, Arturo Corbatón-Anchuelo, Guillermo Martínez Díaz-Guerra, Félix Bermejo Pareja
Diabetes & Metabolism.2025; 51(4): 101656. CrossRef
Bone Health in Type 1 and Type 2 Diabetes: Pathophysiological Mechanisms, Clinical Implications, and Management Strategies
Hermine Carine Pouabe Epse Bodah, Suraiya Rahman Shifa, Sara Saleh, Tuba Abeer Hashmi, Tuleen Al Shawa, Badreshiya Kajal Akshaykumar, Nabeel Sufwan, Rajvinder Kaur, Andrii Shevchuk, Usman Ul Haq, Manju Rai
SN Comprehensive Clinical Medicine.2025;[Epub] CrossRef
Inflammatory impact of cigarette smoking on bone function and structure; a review of evidence
Yashar Shahbaz, Rasoul Shirmohammadi, Shirin Shamsghahfarokhi, Hooman Esfahani, Mobin Forghan, Hojjat Eghbali Jelodar, Leila Ashrafi, Mohammad Mousavi
Journal of Parathyroid Disease.2025; 13: e13302. CrossRef
Influence of quitting smoking on diabetes-related complications: A scoping review with a systematic search strategy
Magdalena Walicka, Arkadiusz Krysiński, Giusy Rita Maria La Rosa, Ang Sun, Davide Campagna, Agostino Di Ciaula, Tabinda Dugal, Andre Kengne, Phuong Le Dinh, Anoop Misra, Riccardo Polosa, Syed Abbas Raza, Cristina Russo, Roberta Sammut, Noel Somasundaram
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(5): 103044. CrossRef

Review Articles

Diabetes, obesity and metabolism
Initial Combination Therapy in Type 2 Diabetes: Ji Yoon Kim, Nam Hoon Kim; Endocrinol Metab. 2024;39(1):23-32. Published online November 30, 2023; DOI: https://doi.org/10.3803/EnM.2023.1816

33,820 View
1,294 Download
13 Web of Science
19 Crossref

Abstract PDF PubReader ePub

Type 2 diabetes (T2D) is a progressive disease in which it is challenging to achieve long-term durable glycemic control. However, intensive glycemic control is crucial for preventing diabetes-related complications. Previous studies showed that monotherapy with a stepwise add-on approach was seldom effective for long-term durable glycemic control. Combination therapy, which refers to the use of two or more drugs to control hyperglycemia, has multiple benefits, including the ability to target a variety of pathophysiological processes underlying hyperglycemia. In clinical trials, initial combination therapy showed better glycemic control than monotherapy or a stepwise approach. Emerging evidence indicates that initial combination therapy is associated with preserved β-cell function and fewer complications in T2D. However, cost-effectiveness and adverse events with combination therapy are issues that should be considered. Therefore, initial combination therapy is an important option for patients with T2D that clinicians should consider with a view toward balancing benefits and potential harms. In this review, we summarize the literature addressing initial combination therapy in T2D, and we suggest optimal strategies based on clinical situations and patient characteristics.

Citations

Citations to this article as recorded by

Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes
Ji Yoon Kim, Jee Hee Yoo, Nam Hoon Kim, Jae Hyeon Kim
Journal of Diabetes Science and Technology.2026; 20(3): 775. CrossRef
Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Development and Validation of a High‐Performance Liquid Chromatography Coupled With Photodiode Array Detection Method for the Simultaneous Analysis of Metformin, Cyanoguanidine, and Antidiabetic Agents in Fixed‐Dose Combinations
Gökhan Bayrak, Selen Al, Aykut Kul, Armağan Önal
SEPARATION SCIENCE PLUS.2026;[Epub] CrossRef
Ethnic Disparities in Glycemic Control among Malaysian Adults with Type 2 Diabetes: A Retrospective Multivariable Analysis
Fikry Ahmad, Suhaili Abubakar, Sharifah Sakinah Syed Alwi, Ng Ooi Chuan, Hasni Idayu Saidi
Journal of Racial and Ethnic Health Disparities.2026;[Epub] CrossRef
GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes
Kunal Zaveri, Girish Kulkarni, Rathish Nair, Govarthanan Shanmugan, Shubhada Amol Dharmadhikari, R. P. S. Makkar, Rahul Jalgaonkar, B. D. Chatterjee, Krishnaprasad Korukonda, Natural Hoi Sing Chu
PLOS One.2026; 21(2): e0337107. CrossRef
A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy
Suhas G Erande, Amar Raykantiwar, Vivek Shejole, Rashmi GR, Animesh Maiti, A.S. Veeramani Kartheek, Mohamed Hanifah, Richa Giri, Sharvil Gadve, Arindam Ray, Kunal Thakkar, Balram Sharma, Saket Kant, Abhyudaya Verma , Yogesh Yadav, Hiren Prajapati, Honey D
Cureus.2026;[Epub] CrossRef
Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy
Hariballav Mahapatra, Piyush Kumar Gupta, Ajo Paul, Amit Nampalliwar, Manju Bansal, Baijnath Das, K. Parameswaran Namboothiri
Cureus.2026;[Epub] CrossRef
Clinical Experience and Outcomes with Triple-drug Fixed-dose Combination Therapy (Sitagliptin + Dapagliflozin + Metformin Sustained-Release Tablets) in Type 2 Diabetes Mellitus Management: A Real-world Observational Survey of Clinician Perspectives
Manoj Arajanbhai Suva
Archives of Medicine and Health Sciences.2026; 14(1): 61. CrossRef
Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis
Rongfang Guo, Shuying Zhang, Anyao Li, Ping Zhang, Xin Peng, Xiaoyan Lu, Xiaohui Fan
Pharmacological Research.2025; 215: 107711. CrossRef
Factors associated with prescription of modern antidiabetics in newly diagnosed patients with type 2 diabetes. a real-world data study in a Spanish region
Irantzu Bengoa-Urrengoechea, Isabel Aguilar-Palacio, María José Rabanaque, María Jesús Lallana, Adriana Gamba Cabezas, Sara Malo
Frontiers in Pharmacology.2025;[Epub] CrossRef
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study
Ji Yoon Kim, Nam Hoon Kim, Jiyoon Lee, Dong-Hoon Kim, Sin Gon Kim
European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(7): 620. CrossRef
High-performance liquid chromatography method for simultaneous determination of the degradation products of metformin hydrochloride and vildagliptin
Amra Demirović, Alija Uzunović, Anisa Veledar-Hamalukić
European Journal of Pharmaceutical Sciences.2025; 214: 107268. CrossRef
Cyclic amines-modified metformin derivatives with enhanced glucose uptake activity
Muhammad Fathiy Mutalabisin, Nor Akmalyati Sulong, Nader Ghaffari Khaligh, Vannajan Sanghiran Lee, Nurshamimi Nor Rashid, Mohd Rafie Johan, Chin Fei Chee
Results in Chemistry.2025; 18: 102830. CrossRef
Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2025; 49(6): 1287. CrossRef
Anti-Senescence Effect of Inhibiting Sodium-Glucose Cotransporter 2 and α-Glucosidase in a Type 2 Diabetes Mellitus Animal Model
Serin Hong, Byung Soo Kong, Hyunsuk Lee, Young Min Cho
Diabetes & Metabolism Journal.2025; 49(6): 1229. CrossRef
Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus
Cheng Luo, Xian-Mei Yu, Liang-Yan Hua, Mei-Qi Zeng, Hui Xu, Cheng-Zheng Duan, Shi-Yu Xu, Da Sun, Li-Ya Ye, Dong-Juan He
World Journal of Stem Cells.2025;[Epub] CrossRef
Balancing Bleeding and Ischemic Risks: A Systematic Review of Dual Versus Triple Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation
Abubakar Gapizov, Ahmad Mohammad, Shivam Singla, Bhavna Singla, Saifullah Syed, Sunita Kumawat, Zulqurnain Ali
Cureus.2025;[Epub] CrossRef
GLYCEMIC CONTROL AND COMORBIDITIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A GENDER-BASED STUDY IN HEALTH FACILITIES OF DUHOK, IRAQ
Hozan Qasim Hussein, Hileen Mustafa Haji, Milat Hussein Mustafa
Health Problems of Civilization.2025;[Epub] CrossRef
Vector of glycated hemoglobin in the formation of dysglycemia in postmenopause: Emphasis on early diagnosis and therapy
L. A. Ruyatkina, D. S. Ruyatkin, L. V. Shcherbakova, I. S. Iskhakova
Meditsinskiy sovet = Medical Council.2024; (16): 135. CrossRef

Miscellaneous
Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer: Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park; Endocrinol Metab. 2023;38(6):619-630. Published online November 21, 2023; DOI: https://doi.org/10.3803/EnM.2023.1814

10,836 View
218 Download
5 Web of Science
6 Crossref

Abstract PDF PubReader ePub

Metabolism is a dynamic network of biochemical reactions that support systemic homeostasis amidst changing nutritional, environmental, and physical activity factors. The circulatory system facilitates metabolite exchange among organs, while the endocrine system finely tunes metabolism through hormone release. Endocrine disorders like obesity, diabetes, and Cushing’s syndrome disrupt this balance, contributing to systemic inflammation and global health burdens. They accompany metabolic changes on multiple levels from molecular interactions to individual organs to the whole body. Understanding how metabolic fluxes relate to endocrine disorders illuminates the underlying dysregulation. Cancer is increasingly considered a systemic disorder because it not only affects cells in localized tumors but also the whole body, especially in metastasis. In tumorigenesis, cancer-specific mutations and nutrient availability in the tumor microenvironment reprogram cellular metabolism to meet increased energy and biosynthesis needs. Cancer cachexia results in metabolic changes to other organs like muscle, adipose tissue, and liver. This review explores the interplay between the endocrine system and systems-level metabolism in health and disease. We highlight metabolic fluxes in conditions like obesity, diabetes, Cushing’s syndrome, and cancers. Recent advances in metabolomics, fluxomics, and systems biology promise new insights into dynamic metabolism, offering potential biomarkers, therapeutic targets, and personalized medicine.

Citations

Citations to this article as recorded by

Development and validation of an interpretable machine learning model for predicting intraoperative HDI in PPGL based on intratumoral and peritumoral CT radiomics
Shurong Li, Zhiqiang Zhang, Yubing Zhang, Yulong Chen, Jian Ling, Qingfen Hong, Xuanling Wu, Fufu Zheng, Cheng Luo
European Journal of Radiology.2026; 195: 112559. CrossRef
Features of bioenergetic metabolism in physiological and pathological conditions: focus on oncogenesis
A. S. Zhdanova, Z. E. Belaya, G. A. Melnichenko
Problems of Endocrinology.2026; 71(6): 56. CrossRef
Advances in Intestinal Glucose Absorption Regulation for Ruminant Energy Efficiency Improvement
Yan Ye, Xiongfei Zhang, Junhu Yao, Xinjian Lei
Animals.2026; 16(4): 659. CrossRef
Factors Associated with the Development of Skin Lesions in Hospitalized Patients Admitted to a Nursing Preventive Care Program in Colombia
Gaby E. Escobar, Ángela F Espinosa, Olga L. Cortés, Nicolás Molano González
Investigación y Educación en Enfermería.2025;[Epub] CrossRef
Editorial: Tumor metabolism and programmed cell death
Dan-Lan Pu, Qi-Nan Wu
Frontiers in Endocrinology.2024;[Epub] CrossRef
Molecular subtypes of clear cell renal carcinoma based on PCD-related long non-coding RNAs expression: insights into the underlying mechanisms and therapeutic strategies
Han Wang, Yang Liu, Aifa Tang, Xiansheng Zhang
European Journal of Medical Research.2024;[Epub] CrossRef

First
Prev
Page of 5
Next
Last

Search